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Abstract
Breast cancer survivors (BCS) account for the largest group of cancer survivors living in
the United States and they often experience lingering physical symptoms that may affect quality
of life, with fatigue and pain the most commonly reported. This genetic research study was
conducted within a parent R01 study, with the purpose of exploring associations between genetic
variants and fatigue and pain symptoms and the Mindfulness-Based Stress Reduction for Breast
Cancer (MBSR(BC)) program. The aims of this study were to: 1) identify specific genotypes
involved in fatigue and pain symptoms, and 2) explore whether single nucleotide polymorphism
(SNP) rs1800795 in gene IL6, SNP rs16944 in gene IL1B, and SNP rs4680 in gene COMT,
moderate the effects of the MBSR(BC) intervention on fatigue and/or pain symptoms.
As part of a larger R01 trial, one-hundred-fifty-eight participants were randomized to
either a six-week MBSR(BC) intervention or Usual Care (UC). Data were collected at baseline,
six-week, and 12-weeks on subjective measures of pain, fatigue, along with demographic and
clinical history information. In addition, DNA was collected for genotyping among the 158
participants using the PCR analysis method. For Aim 1, one-way linear trend analysis of
variances (ANOVAs) were implemented to explore associations between the SNPs in genes with
subjective symptom measures of pain and fatigue. For Aim 2, comparison of mean scores along
with linear mixed model (LMM) analyses were used to explore if the patient’s SNPs moderated
the effects of the MBSR(BC) intervention on fatigue and pain symptoms.
Results found the mean age of the total sample was 58.4 years and 89% were White, nonHispanic. Although participants were randomized 1:1 to either the MBSR(BC) or UC groups, chi
square analyses found that there was a significant difference for time since treatment, with the
vii

UC group being closer to treatment end (< 1 year) than the MBSR(BC) group (p < .05). No other
statistically significant differences between groups for baseline demographic or clinical
characteristics were found. For Aim 1, one-way linear trend ANOVAs among fatigue and pain
scores and the three SNPs (COMT rs4680, IL1B rs16944, IL6 1800795) included as part of this
study, fatigue and/or pain, resulted in no statistically significant associations (p > .05). Linear
Mixed Model (LMM) analyses, implemented to assess the between-group interactions between
pain and/or fatigue symptom, time, and SNP, resulted in no statistically significant findings for
SNP rs4680 in COMT and SNP rs16944 in IL1B, however significant findings were found for the
interaction between assignment (MBSR(BC) versus UC) and genotype for SNP rs1800795 in
IL6. Second, a comparison of means suggests that participants in the MBSR(BC) group who had
CG genotype for SNP rs1800795 in IL6 benefited more from the intervention than those with CC
or GG genotypes for fatigue severity, fatigue interference, pain severity, and pain interference,
with small to large effect sizes ranging from d = 0.38 to d = 0.72. Although this genetic study
was exploratory in nature, the results suggests that the effects of the MBSR(BC) program may be
moderated by SNPs in genes that are involved in cytokine production, which means that BCS
with specific genotypes experience a greater improvement in symptoms than those with other
genotypes. The results of this study also suggest that further research is needed, with larger
sample sizes, to assess the genetic moderation of symptoms experienced by BCS.
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Chapter One
Introduction
Background
Breast cancer in the United States. Breast cancer is the most prevalent form of cancer
in women and in 2018 in the United States, there were over 3.1 million women with a history of
breast cancer, including patients and survivors (U.S. Breast Cancer Statistics, 2018). Breast
cancer is increasing in prevalence and as new discoveries of improvements for the detection and
treatment of cancers rise, the number of cancer survivors continues to rise also (Siegel, Miller, &
Jemal, 2018). Breast cancer is expected to account for 30% of all cancer cases in 2018
(American Cancer Society, 2017) and approximately one in eight women in the United States
will develop invasive breast cancer at some point in life (U.S. Breast Cancer Statistics, 2018).
Breast cancer survivors comprise the largest group of cancer survivors living in the United
States, with an estimated five-year breast cancer survival rate of 91% in 2017 (American Cancer
Society, 2017). Unfortunately, many BCS suffer from a multitude of adverse symptoms after
treatment that can affect quality of life.
Physical symptoms and quality of life in women with breast cancer. Despite
successful treatment, BCS often experience lingering physical symptoms that may affect their
quality of life. Survivors of breast cancer report pain, fatigue, neuropathies such as weakness,
tingling, and numbness, sexual dysfunction, bone and joint problems, lymphedema, skin
changes, memory loss, and decreased immune function after cancer treatment ends. Fatigue and
pain are reported to be the most commonly experienced physical symptoms and are often co1

occurring (Reich et al., 2017a; Miaskowski et al., 2007), and have been shown to be strongly
associated with satisfaction with quality of life (Gavric-Kostic, 2016; Hamer et al., 2016).
Fatigue in BCS. Fatigue is a very common symptom that plagues BCS and the National
Cancer Institute (2015) has included cancer-related fatigue as one of the “first tier high-priority
areas for research.” In a study by Lengacher et al. (2012), 85% of BCS suffered from fatigue,
making it one of the top two most common adverse effects of cancer treatment. Women with
breast cancer report fatigue to be one of the most distressing symptoms related to cancer
treatment, which has been shown to be strongly associated with satisfaction with quality of life
(Bower, 2014; Gupta, Lis, & Grutsch, 2007). Cancer patients can experience fatigue long after
treatment ends, and chronic fatigue has been defined as fatigue lasting for a period of at least six
consecutive months (Wessely, Hotopf, & Sharpe, 1998). Approximately one-third of extensively
treated disease-free BCS experience chronic fatigue up to ten years after breast cancer diagnosis
(Bower, 2014; Bower et al., 2006; Reinertsen et al., 2010; Servaes, Gielissen, Verhagen, &
Bleijenberg, 2006). It is unknown how cancer treatments cause fatigue, but common cancer
treatments contributing to cancer-related fatigue include chemotherapy, radiation therapy,
biologic therapy, and surgery (National Cancer Institute, 2014).
Pain in BCS. Pain is highly prevalent among BCS. Breast cancer survivors comprise the
greatest percentage of cancer survivors reporting problems related to pain or discomfort (Jefford
et al., 2017). In a study by Lengacher et al. (2012), 60% of BCS suffered from pain, and a study
on a specific category of pain such as persistent pain found that approximately 25-60% of
women experience persistent pain after mastectomy (Gartner et al., 2009), making pain one of
the top two most common adverse effects of cancer treatment. Pain is also highly deleterious,
with an approximate rate of 5-10% of cancer survivors experiencing chronic pain so severe that

2

it interferes with functioning (Glare et al., 2014). Pain may plague BCS for years after treatment
ends.
The physical symptom experience and genetics. Cancer survivors have their own
unique symptom experiences, with some suffering more or less from post-treatment symptoms
(Avis, Levine, Marshall, & Ip, 2017). The variance in frequency and intensity of symptoms
experienced by BCS may be partly explained by individual genetic factors (Doong et al., 2015;
Shi et al., 2015). Genetic factors predicting patient outcomes from adverse symptoms such as
pain and fatigue may lead to better quality of life for BCS utilizing personalized therapies based
on individual needs. Genetics and genomics in cancer screening, diagnosis, treatment, and
particularly for symptom management after behavioral interventions, are increasingly in the
forefront of cutting edge research. Aside from screening purposes, focus on genetics may prove
to be an important piece in predicting symptom outcomes experienced by BCS. The assessment
of common genetic variations can be beneficial for outcomes in patients with cancer, and with
the revolutionary advances in molecular technology, associations between genetic variations and
symptoms experienced by cancer patients are of great importance. There is a need to
individualize treatment for fatigue and pain in women with breast cancer, particularly BCS, and
genetic studies can contribute to the field of precision medicine, to tailor complementary and
alternative medicine therapies to best suit patients’ needs (Grady & Gough, 2015).
Interventions to improve fatigue and pain in BCS. According to the Department of
Health, Macmillan Cancer Support, and NHS Improvement’s National Cancer Survivorship
Initiative Vision (2010), as the growth of cancer survivors increases, future survivorship care
should be tailored to meet the needs of individual cancer survivors and support for selfmanagement care needs to be expanded. The American Cancer Society and American Society of
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Clinical Oncology developed and released a Breast Cancer Survivorship Care Guideline in 2015,
which details recommendations for managing side effects. Current survivorship care for posttreatment symptoms in BCS include pharmacological and non-pharmacological therapies.
However, as many pharmacological treatments cause other unwanted side effects, evidence
supports the use of non-pharmacological treatments, which appear to be a safer alternative
(Blaes, Kreitzer, Torkelson, & Haddad, 2011). Multiple non-pharmacological interventions have
been used for the management of post-treatment side effects after breast cancer. Nonpharmacological strategies include psychological and behavioral interventions, exercise
interventions, and complementary and alternative medicine techniques (Palesh et al., 2017).
Currently, non-pharmacological level one recommendations for treatment of fatigue in
cancer survivors are exercise and cognitive behavioral therapy (Runowicz et al., 2016).
Unfortunately, an estimated up to 70% of BCS do not discuss exercise with their oncology
providers or exercise according to public health guidelines set forth by the American College of
Sports Medicine (Palesh et al., 2017). In addition, age, physical limitations, and other
comorbidities may pose a problem for cancer survivors when participating in an exercise
program. Fortunately, other interventions are promising and have been found to improve the
quality of life in BCS by reducing adverse side effects that sometimes remain after cancer
treatment ends, including stress-reducing techniques (Carlson et al., 2013) such as MindfulnessBased Stress Reduction (Lengacher et al., 2016) and acupressure (Rosenberg, 2016; Yeh et al.,
2016), acupuncture (Tao et al., 2016) and massage (Kinkead et al., 2018).
Non-pharmacological level one recommendations for the management of pain in BCS
include physical activity and acupuncture (Runowicz et al., 2016). Acupuncture has been found
to be an effective treatment for pain in cancer patients (Tao et al., 2016), as well as exercise
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interventions (Galiano-Castillo et al., 2016). Unfortunately, many BCS who were treated with
aromatase inhibitors experience musculoskeletal symptoms (aromatase inhibitor-induced
arthralgia) resulting from the medication, and although exercise is recommended to treat this side
effect, BCS experiencing aromatase inhibitor-induced arthralgia report exercising less than those
who were not treated with aromatase inhibitors, possibly as a result of impaired lower extremity
function and joint pain (Brown et al., 2014).
Mindfulness-based stress reduction. Mindfulness-Based Stress Reduction for Breast
Cancer (MBSR(BC)) is a stress-reducing technique that has been proven effective in improving
symptoms experienced by women with breast cancer after treatment (Lengacher et al., 2012).
The MBSR(BC) program is a six-week complementary alternative medicine program adapted
and tested by Lengacher et al. (2009) from Dr. Jon Kabat-Zinn’s original eight-week program
aimed at reducing stress through self-regulation of symptoms to improve the quality of life in
BCS (Lengacher et al., 2009). Positive effects have been found through its utilization towards
treating anxiety, cognitive impairment, depression, fatigue, fear of recurrence, and sleep
disturbances in BCS (Lengacher et al., 2009, 2015, 2016, 2017).
Precision medicine in cancer survivorship. Precision medicine is a medical model that
suggests that healthcare be personalized to each individual patient, including its selection of
treatments and services, and takes into account each individual’s genetic makeup, or,
“genotype.” The basis for this medical model is that there is no “one size fits all” solution to the
problem; Every patient is unique in the way that they respond to certain therapies. Individual
biological responses may vary and often are due in part to the genes within their DNA, which
encode amino acid sequences, which shape the way bodies function. A treatment that works for
one patient may not be as effective for another (Ziegelstein, 2017). Although the concept of
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precision medicine has existed for some time, in 2015 during his State of the Union address,
United States President Barack Obama declared the launch of the Precision Medicine Initiative,
investing $215 million in 2016 towards biomedical advances that will supply healthcare
providers with new knowledge and tools to personalize treatments for the best outcomes.
Statement of the Problem
The American Cancer Society and the American Society of Clinical Oncology (2016)
developed breast cancer survivorship care guidelines for assessing and managing physical,
psychological, and social long-term effects that recommended that interventions be tailored to
the needs and abilities of the individual breast cancer survivor (Runowicz et al., 2016).
Statement of the Purpose
The purpose of this study was to explore potential genetic variations that may or may not
moderate pain and fatigue symptoms among women with BC who participated in a MBSR(BC)
program. This study was conducted in part as a secondary data analysis within the RO1 MBSR
Symptom Cluster Trial for Breast Cancer Survivors/1R01CA131080.
Research Aims and Hypotheses
The overall objective of this research study was to explore whether individual genetic
variants moderate improvement of fatigue and pain symptoms resulting from the MBSR(BC)
program. It was hypothesized that specific single nucleotide polymorphisms (SNPs) of genes are
associated with fatigue and pain in BCS, and may moderate improvement from MBSR(BC).
The primary study aims of this research are as follows:
Aim 1: To identify the specific genotypes related to symptoms of fatigue and pain among BCS.
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Hypothesis 1: It is hypothesized that specific genotypes in SNPs COMT rs4680, IL1B
rs16944, and IL6 rs1800795 are associated with higher or lower levels of pain and fatigue among
BCS.
Aim 2: To explore whether the single nucleotide polymorphism (SNP) rs1800795 in gene IL6,
SNP rs16944 in gene IL1B, and SNP rs4680 in gene COMT, moderate the effects of the
MBSR(BC) intervention on fatigue and/or pain symptoms.
Hypothesis 2: It is hypothesized that the SNPs IL6 rs1800795, IL1B rs16944, and COMT
rs4680, will positively moderate symptoms of fatigue and pain among BCS participating in the
MBSR(BC) intervention compared to the UC group.
Definitions of Relevant Terms
The definitions of relevant terms that were used in this study are as follows:
1. Gene: The basic unit of heredity, made up of DNA, which act as instructions to make
proteins and determines characteristics (Genetics Home Reference, 2018a).
2. Genotype: The two alleles inherited for a particular gene; An individual’s collection of
genes (National Human Genome Research Institute, 2018).
3. Fatigue: The subjective phenomenon of a sense of persistent tiredness or exhaustion
that is commonly distressing, measured by the Fatigue Symptom Inventory (Donovan
& Jacobsen, 2011).
4. Fatigue Severity: A subscale of the Fatigue Symptom Inventory that assesses the level
of fatigue in the past week as well as current fatigue (Radiation Therapy Oncology
Group, 2010).
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5. Fatigue Interference: A subscale of the Fatigue Symptom Inventory that assesses the
degree to which fatigue in the past week hindered on daily activities and mood
(Radiation Therapy Oncology Group, 2010).
6. Mindfulness-Based Stress Reduction for Breast Cancer (MBSR(BC)): A 6-week clinical
program designed to assist BCS in self-managing stress and symptoms through
meditative activities (Lengacher et al., 2009; Reich et al., 2017a).
7. Pain: An unpleasant feeling experienced physically or emotionally, often associated
with previous tissue damage, measured by the Brief Pain Inventory (Cleeland, 2009;
IASP Task Force on Taxonomy, 2017).
8. Pain Severity: A subscale of the Brief Pain Inventory that assesses the degree of pain
intensity (Cleeland, 2009).
9. Pain Interference: A subscale of the Brief Pain Inventory that assesses the impact of
pain on functioning in daily activities (Cleeland, 2009).
10. Single Nucleotide Polymorphism: A variation in a gene that represents a difference in a
single DNA base (Genetics Home Reference, 2018b).
11. Usual Care: Participation by the control group in standard treatments after cancer
treatment ends. Participants were asked not to participate in a mindfulness program
until the study ended (Lengacher et al., 2009; Reich et al., 2017a).
Delimitations
The sample included:
1. Women at least 21 years of age or older
2. Diagnosed with early stage breast cancer (Stage 0-III)
3. Surgically treated (lumpectomy and/or mastectomy)
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4. Are at least two weeks out from or a maximum of two years out from completion of
adjuvant radiation and/or chemotherapy
Exclusion criteria consisted of the following:
1. Diagnosed with advanced stage breast cancer (Stage IV)
2. Self-reported a severe current psychiatric diagnosis
3. Received treatment for recurrent breast cancer
Limitations
This study is the first step in exploring the potential genetic moderation of pain and
fatigue symptoms in BCS participating in a MBSR(BC) program. Study limitations include:
1. This study included only Hispanic and non-Hispanic white women; generalizations to
women of other races and men are limited.
2. The sample size was small for a genetic study. Sufficient statistical power is critical for
the detection of genetic association and moderation studies.
3. This study explores the presence or absence of SNPs and their association with symptoms
experienced by BCS, however, it does not address gene expression, which leaves an open
gap between the presence of SNPs and their effects on protein synthesis.
4. Although genotype was identified for genes involved in inflammatory and antiinflammatory pathways, there were no direct measures of systemic levels of circulating
IL6 and IL1B, which would have provided supplementary information on the latent
mechanisms for pain and fatigue severity.
5. There was no assessment of fatigue or pain prior to a breast cancer diagnosis, so it is
impossible to determine if there were pre-existing symptoms prior to cancer treatment.
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6. As there was no healthy control group, inferences cannot be made about the relationship
between these genetic variations and fatigue and pain in the general population or in
people with other types of cancer (prostate, lung, etc).
Significance of the Study
There is limited empirical knowledge and data regarding the relationships between
fatigue and pain-associated single nucleotide polymorphisms (SNPs), and mind-body therapies
such as the MBSR(BC) program. This study will contribute to symptom science and precision
medicine by exploring these associations and disseminating findings to target optimal therapies
for BCS based on their genetic profiles, which may help improve quality of life. Although this
study is exploratory in nature and lacks the larger sample size needed for the precision of genetic
association research, it is anticipated that this study will warrant future research involving larger
clinical trials on the genetic moderation of symptoms experienced by BCS as well as the use of
MBSR(BC) to treat such symptoms.
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Chapter Two
Literature Review
Introduction
Chapter two introduces the theoretical framework, the hypothesized research model, and
a review literature on the study variables in this dissertation. First, a review of empirical research
will be presented on pain and fatigue symptoms experienced by BCS. This review is followed by
a review of empirical literature on genetic variants (single nucleotide polymorphisms) associated
with pain and fatigue. Concluding this review is a review of complementary and alternative
medicine therapies used to treat pain and fatigue, particularly the Mindfulness-Based Stress
Reduction for Breast Cancer Program, which is the intervention implemented in this study.
Theoretical Framework and Hypothesized Research Model
This research was guided by a hypothesized research model, which was adapted from a
logic model based upon the Psychosocial Nursing Research Model (Evans (1992). The
hypothesized research model postulates that:
•

Outcomes resulting from the Mindfulness-Based Stress Reduction for Breast Cancer
(MBSR(BC)) program are moderated by genetic variations such as single nucleotide
polymorphisms (SNPs).

•

Changes in physical symptoms (fatigue and pain) resulting from MBSR(BC) are
expected to improve from baseline to 6 and 12-week assessments to a greater or lesser
degree based on genetic profile.
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Figure 1. Hypothesized Research Model

Review of Empirical Literature
This review of empirical literature examined the variables within this study. First, a
review of research on physical symptoms experienced by BCS, with a particular focus on fatigue
and pain as they are the main symptom outcomes of this study, are presented. Next, genetic
polymorphisms that have been found to be associated in fatigue and pain symptom pathways are
reviewed, followed by mind-body interventions such as MBSR(BC), which was used to treat
fatigue and pain symptoms by this study’s participants in the intervention group.
Post-treatment physical symptoms in BCS. Breast cancer survivors commonly suffer
from treatment-related symptoms that may linger for years after treatment ends, which are often
distressing (Syrowatka et al., 2017) and decrease quality of life (Gavric-Vukovic-Kostic, 2016;
Koch et al., 2013). In a systematic review of 243 studies by Zomkowksi et al. (2018) on physical
12

symptoms and their interference with the ability to perform work tasks in BCS, the investigators
found that the most commonly reported symptoms included pain, fatigue, lymphedema, arm
and/or breast paresthesia, decreased range of motion and weakness in the upper limbs. Evidence
shows that fatigue and pain are two of the most commonly experienced symptoms in BCS
(Doong et al., 2015; Lengacher et al., 2012). Research also suggests that the patients’ symptoms
vary among individuals, suggesting a need for individualized treatments for symptom
management (Miaskowski et al., 2015).
Pain. The symptom of pain is one of the main subjective variables in this analysis. In this
section, a review of the definition of pain is presented, followed by its prevalence among BCS.
The effects of pain on quality of life in BCS and its interference with the ability to complete
daily activities are also reviewed. Finally, the etiology of pain and its risk factors among BCS are
examined and presented.
Pain is often viewed as the fifth vital sign (Lynch, 2001) and is a complex process that
varies among patients and may be easily misunderstood as it is often defined subjectively and
may seem disproportional to physical signs observed by clinicians. Pain is a subjective
experience and its definition varies. The International Association for the Study of Pain (2017) is
a collaboration of scientists, clinicians, health-care providers, and policymakers who are
dedicated to studying pain and translating research findings into pain relief for patients
worldwide. They have defined pain as “an unpleasant sensory and emotional experience
associated with actual or potential tissue damage, or described in terms of such damage” (Pain,
International Association for the Study of Pain, 2017). Among breast cancer patients, a study by
Hickey et al. (2011) involving persistent breast pain after mastectomy with reconstruction
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described pain as “itching”, “burning”, “tightness”, “ache”, “piercing”, “annoying”,
“exhausting”, and “miserable”.
Pain is highly prevalent among BCS. In a cross-sectional study of 410 BCS by Hamood,
Hamood, Merhasin, and Keinan-Boker (2017) on the prevalence and risk factors associated with
chronic pain and other symptoms related to breast cancer and its treatment, the investigators
found that 74% of BCS reported chronic pain, of which 84% reported the pain to be moderate.
The median since diagnosis was 7.4 years. Pain was assessed using a numeric pain rating scale
from 0 (no pain) to 10 (worst pain imaginable) and higher ratings were found to be significantly
associated with decreased quality of life (p < 0.001), which was assessed using the 36-item shortform health survey (SF-36). Breast cancer survivors were found to have a positive association
with chronic pain if they received mastectomy vs. breast conserving surgery (p = 0.005),
radiotherapy vs. non-radio therapy (p = 0.003), regional breast cancer vs. localized at time of
diagnosis (p < 0.001), younger vs. older age (p = 0.002), and time since diagnosis (p < 0.001).
The pain that BCS experience may often affect quality of life. A study by Gavric &
Vukovic-Kostic (2017) involving BCS found that pain negatively influenced quality of life. The
authors assessed quality of life using a self-report questionnaire (QLQ-C30- The Core Quality of
Life Questionnaire of The European Organization for Research and Treatment of Cancer, version
3.0) among 100 women. The questionnaire consisted of five functional scales: Physical
functioning; Role functioning; Emotional functioning Cognitive and Social functioning; and
three scales of symptoms: pain, nausea/vomiting, Dyspnea, Insomnia, Appetite loss,
Constipation and Diarrhea. Although there were statistically significant differences in emotional,
role, and social functions, one of the most influential was the symptom of pain. In another study,
Rim et al. (2017) investigated the quality of life of BCS during the first three years after breast
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cancer treatment including radiotherapy. Their large sample of 1156 participants were drawn
from 17 hospitals and the patients were separated into three groups (first, second, and third year
from the end of radiotherapy). Participants were asked to complete two self-administered quality
of life questionnaires: The breast cancer-specific module of the EORTC Quality of Life
Questionnaire and the 5-dimensional questionnaire by the EuroQol group (EQ-5D). It was found
through the 3-grade Likert scale of the EQ-5D that the worst grades for problems related to
health status (2 = some/moderate problem; 3 = extreme problem) were in the pain/discomfort
category among the total participants (p < 0.001). Results also showed that pain/discomfort was
significantly associated with less satisfaction with quality of life but improved with each time
period (i.e. year one to year two, year two to year three) (p < 0.001).
Pain can be debilitating after breast cancer treatment and can interfere with the ability to
carry on with daily activities. In a cross-sectional study by De Groef et al. (2017) on pain
characteristics and their contribution to upper limb dysfunction in 274 BCS the investigators
found that pain quality (p = 0.003), pain intensity (p = 0.005), pain catastrophizing (p < 0.001),
and signs of central sensitization (p < 0.001) contributed to limb dysfunction. Risk factors
including treatment-related variables, patient-related variables, and impairment-related variables
were analyzed by bivariable and multivariable analyses. Upper limb function was assessed using
the Disability of Arm, Shoulder, and Hand (DASH) questionnaire. The mean time after surgery
was 1.5 years, which reveals that pain resulting from breast cancer treatment can affect long-term
functioning (i.e. more than one year after surgery).
A variety of risk factors has been found to contribute to the pain experience in BCS. A
systematic review of literature and meta-analysis by Leysen et al. (2017) was performed on risk
factors of chronic pain in BCS. The authors included 17 eligible studies and 17 risk factors for
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the development of chronic pain in their meta-analysis. They found that eight (obesity/Body
Mass Index >30, education <12-13 years, lymphedema, non- or ex-smoker, axillary lymph node
dissection, chemotherapy, hormone therapy, and radiotherapy) out of 17 risk factors were
significantly associated (p < 0.05) with increased risk of chronic pain development in breast
cancer survivorship. Lymphedema was found to be the strongest risk factor (OR: 2.58, 95% CI
1.93-3.46, p < 0.00001).
The etiology of pain is not fully understood. Pain is considered a neurotoxic symptom
resulting from breast cancer and its treatment. In a study by Lacourt and Heijnen (2017) on the
mechanisms of neurotoxic symptoms resulting from breast cancer and its treatment, the authors
found that neuro-inflammation related to stress, cancer treatment, or cancer-related stress is a
predictor of neurotoxic symptoms such as pain both during and after breast cancer treatment.
Since stress is commonly experienced by BCS and is often prolonged over a long period of time,
the stress response is altered and thus stress hormones have a diminished capacity to regulate the
inflammatory response, leading to neuro-inflammation. The authors also suggested that
mitochondrial dysfunction results from breast cancer and its treatment, which may potentiate
neurotoxic symptoms such as pain. It is also suggested that changes in levels of pro- and antiinflammatory cytokines and genes associated with their pathways are associated with pain in
cancer patients. Miaskowski and Aouizerat (2012) found that among cancer patients, pro- and
anti-inflammatory cytokines and their genes, including IL1B, IL2, IL4, IL6, IL8, and TNF-a are
potential biomarkers for pain.
Additional biomarkers that have been found in the literature to contribute to the etiology
of pain include neurotransmitter (catechols: dopamine, adrenaline, and noradrenaline) and opioid
receptor dysregulation. Miaskowski and Aouizerat (2012) found that among cancer patients,
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opioid receptors and neurotransmitters such as COMT and five hydroxtryptamine (5-HT) and
genes (COMT, 5-HTT, OPMR1) involved in their production pathways, are potential biomarkers
for pain.
In summary, pain is a subjective experience that has multiple definitions. It is highly
prevalent in BCS, distressing, and often affects their quality of life and the ability to carry on
everyday activities. Its etiology is often misunderstood, however, it is suggested that circulating
pro- and anti-inflammatory cytokines and genes involved in their pathways, as well as other
biomarkers including neurotransmitters and opioid receptors, all play a part in the pain
experience.
Fatigue. The symptom of fatigue is another main variable in this study. In this section, a
review of fatigue will be presented, including its definition found in the literature, as well as its
prevalence among BCS. The etiology of fatigue will also be reviewed.
Fatigue is a subjective experience and its definition varies in the literature. The Farlex
Partner Medical Dictionary (2012) defines fatigue as “physical and/or mental exhaustion that can
be triggered by stress, medication overwork, or mental and physical illness or disease.” A crosssectional study by Bower et al. (2000) described fatigue as a subjective feeling of tiredness,
weakness, and lack of energy, in their article on the occurrence of fatigue and its correlates and
impact on quality of life in their sample of 1,957 BCS. Additionally, Cleveland Clinic (2017)
describes fatigue as “a daily lack of energy; an unusual or excessive whole-body tiredness, not
relieved by sleep.” It is also worth mentioning that cancer-related fatigue has been differentiated
from fatigue caused by daily life, as cancer-related fatigue is often worse, lasts longer, is
unpredictable, and increases distress, according to the American Cancer Society (American
Cancer Society, Cancer Related Fatigue, 2016). Cancer-related fatigue has also been
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differentiated from healthy fatigue as healthy fatigue, which is more acute and is experienced by
healthy people in their everyday lives, is relieved by sleep and rest and cancer-related fatigue is
not (Berger et al., 2010).
Fatigue is highly prevalent among BCS. According to the National Cancer Institute
(2017), up to 82% of BCS report cancer-related fatigue after treatment ends. In a meta-analysis
of 27 studies including 12,327 BCS by Abrahams et al. (2016), it was found that fatigue
prevalence was 26.9% (95% CI 23.2-31). Breast cancer survivors at a higher risk for severe
fatigue following breast cancer treatment include those with stage II or III cancer, and those
treated with chemotherapy (RR 1.18, 95% CI 1.08-1.28), versus those with stage 0 or I cancer
and not treated with chemotherapy (RR 1.12, 95% CI 1.06-1.19). In addition, chemotherapy puts
BCS at a higher risk for severe fatigue. Abrahams et al. (2016) found that BCS who received a
combination of surgery and radiotherapy had a decreased risk of severe fatigue than those who
also received additional treatments such as chemotherapy (RR 0.83, 95% CI, 0.70-0.98; RR 0.87,
95% CI 0.78-0.96).
Fatigue is suggested to be the result of cancer treatments such as chemotherapy,
radiation, and aromatase inhibitors (Lacourt & Heijnen, 2017; Schmidt et al., 2015; Vichaya et
al., 2015). Although the etiology of fatigue is not fully understood, a hypothesis exists that the
pro-inflammatory cytokine network induces fatigue (DeSanctis et al., 2014; Wang, 2008; Wang
& Woodruff, 2015), which may be activated by cancer itself, its treatment, and psychosocial
stress resulting from the cancer experience. Research suggests pro-inflammatory cytokines
transmit signals to the brain, which in turn facilitate sickness behaviors including fatigue (Lee et
al., 2004; Wang, 2008; Wang & Woodruff, 2015).
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Breast cancer survivors have been reported to have increased pro-inflammatory cytokine
levels, especially more so in those who are also suffering from fatigue. In a cross-sectional study
by Zick et al. (2014) on differences in inflammatory markers between fatigued and non-fatigued
BCS, the investigators performed blood analyses on 29 women (16 fatigued and 13 nonfatigued). Pro-inflammatory cytokine IL-6 was found to be significantly higher (p = 0.03) in
BCS who were experiencing persistent fatigue versus those who were not. This evidence
suggests that on a biological level, patients who produce higher levels of IL-6 are more prone to
experience persistent fatigue after cancer treatment.
In summary, fatigue is a subjective experience commonly reported by BCS. The
diagnosis of cancer and its treatment puts BCS at a higher risk of suffering from fatigue. It is
suggested that increased circulating levels of pro-inflammatory cytokines in the blood induce
fatigue.
Genetic polymorphisms associated with pain and fatigue in cancer survivors.
Genetic polymorphisms are natural variations in DNA sequences that may result in different
types of characteristics and account for varying perceptions and expressions of pain prevalence
and/or intensity. Often, what is less painful for one patient may be more painful for another. In
the following sections, a review of each gene under investigation in this study will be presented,
including genes COMT, IL6, and IL1B, and their relationships to pain and/or fatigue symptoms
that have been previously found in other research studies.
Catechol-O-methyltransferase (COMT). The COMT gene provides instructions for
producing for catechol-O-methyltransferase enzyme, which is responsible for metabolizing
catechol neurotransmitters (dopamine, adrenaline, and noradrenaline) in the brain’s prefrontal
cortex. Within the COMT gene, SNP rs4680 is located on chromosome 22, codon 158, with

19

forward orientation and has been well-studied in its role for the “Warrior vs. Worrier” behavioral
phenotype and has been associated with pain.
In the public database available through the National Center for Biotechnology
Information (NCBI, 2014), the wild-type allele for SNP rs4680 is a (G) and codes for valine
amino acid, which results in more COMT enzyme available to metabolize catechol
neurotransmitters and thus less extracellular dopamine in the pre-fontal cortex, and may be result
in a higher pain threshold and resilience to stress, supporting the “Warrior” behavioral phenotype
(Stein, Newman, Savitz, & Ramesar, 2006). Adversely, the polymorphic (A) substitution alters
the amino acid to a methionine. The result of this substitution is 25% of the enzymatic activity
that a wild-type allele produces, which means less COMT enzyme available to metabolize
catechol neurotransmitters in the brain and more extracellular dopamine in the prefrontal cortex,
which may be responsible for lower pain threshold, increased vulnerability to stress, supporting
the “Worrier” behavioral phenotype (Stein, Newman, Savitz, & Ramesar, 2006).
Abnormalities in the COMT enzyme activity have been found to contribute to pain. In a
systematic review and meta-analysis of COMT gene polymorphism and chronic human pain by
Tammimaki and Mannisto (2012), the authors explored the association between COMT genotype
and three chronic pain conditions: migraine headaches, fibromyalgia, or chronic widespread pain
and chronic musculoskeletal pain. The results of their meta-analysis including eight studies
showed that rs4680 is associated with chronic widespread pain and that the Met allele is a risk
factor (OR = 1.28, 95% CI 1.06-1.55, p = 0.01, n = 3811).
In a study by Knisely et al. (2018) on associations between catecholaminergic genes and
persistent breast pain phenotypes in women following breast cancer surgery, the authors found
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that each additional copy of C allele for SNP rs4680 in COMT was associated with a 3.34-fold
increase in the odds of belonging to the Severe Pain Class (p = .028).
Research by Wang et al. (2015) on the association of SNP rs4680 and pain perception in
285 cancer patients, participants’ pain level was assessed using the Brief Pain Inventory and
genotyping using Polymerase Chain Reaction (PCR) analysis was performed. It was found
through pairwise comparison that COMT wild-type (G) (V108/158M) carriers had higher pain
scores than heterozygous carriers (CG) (p = .013) and homozygous and variant carriers (CC) (p
= .003).
Finally, in a non-cancer population, the major G allele of rs4680 in COMT has been
found to be associated with an increased severity of chronic postsurgical pain (p = .018) (Rut et
al., 2014). Participants were asked to rate their pain on a six-point Likert scale in the Oswestry
Disability Index 12 months after lumbar discectomy. The study reported that the presence of
major (G) alleles increased pain severity in their sample.
Other SNPs in gene COMT have been found to be associated with pain as well. A study
by Lee et al. (2011) found that in their patients undergoing third molar extraction, specific
genotypes for SNPs rs4818 and rs6269 were associated with postoperative pain. Specifically,
those with GG genotype reported sufficient postoperative analgesia versus those with AA or AG
genotype (p < .0001).
In summary, COMT is an enzyme responsible for neurotransmitter production, and
variations in SNPs within the gene have been found to affect pain experiences in patients.
Specific genotypes for SNP rs4680 as well as other SNPs in COMT have been found to result in
higher or lower pain thresholds in both cancer and non-cancer populations, with mixed results
for associations between +/- pain severity and (A) and (G) alleles.
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Interleukin 1 beta (IL1B). The interleukin 1 beta gene provides instructions for
producing pro-inflammatory IL1B cytokine protein that is an important facilitator for
inflammation as well as cellular processes including cell proliferation, cell differentiation, and
cell apoptosis. IL1B has been found to be involved in pain and inflammation (Ren & Torres,
2009). Within the ILB1 gene, SNP rs16944, also known as “-511,” is located on chromosome 2
with forward orientation. In the public database available through the National Center for
Biotechnology Information (NCBI, 2014), the wild-type allele for SNP rs16944 is a (G) while
the polymorphic allele is an (A).
In a study by Kober et al. (2016) on the association between SNP rs16944 and fatigue
levels, the authors evaluated fatigue levels using the Lee Fatigue Scale in (n = 398) and
performed genotyping in BCS following breast cancer surgery. Results showed that those
possessing the polymorphic (A) allele of SNP rs16944 in IL1B gene were likely to experience
higher levels of fatigue than those possessing the wild-type (G). However, in a regression
analysis, those possessing a GG or AG genotype were found to have a 2.98-fold higher odds of
scoring higher on the Lee Fatigue Scale those possessing the AA genotype.
A study of 53 prostate cancer patients by Jim et al. (2012) examined the relationship
between fatigue and SNP rs16944 in gene IL1B. Fatigue was assessed using the Fatigue
Symptom Inventory at two time points following androgen deprivation therapy for treatment of
prostate cancer and genotyping was performed via PCR analysis method. The results were nonsignificant for genotype by time interaction for fatigue and SNP rs16944 (p’s > 0.46)
The results of a study by Collado-Hidalgo et al. (2008) suggest that a variant in SNP
rs16944 in IL1B predicted fatigue (95% CI = 0.91–16.6, p = .007) in their sample of 47 BCS.
Fatigue was assessed using the Multidimensional Fatigue Symptom Inventory (MFSI) and DNA
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were genotyped using PCR analysis. An association was found between possessing at least one
cytosine and fatigue (95% CI = 0.91–16.6, p = .007).
Interleukin 6 (IL6). The interleukin 6 gene provides instructions for producing IL6
cytokine protein that plays a role in the inflammation response and maturation of B cells. Within
the IL6 gene, SNP rs1800795, located on chromosome 7 with forward orientation, is also known
as the “-174 polymorphism.” In the public database available through the National Center for
Biotechnology Information (NCBI, 2014), the wild type allele for SNP rs1800795 is a (G).
Research has found that a polymorphic (C) substitution results in less IL6 production in humans
than those possessing the wild-type allele (G) (Fishman et al., 1998). Pro-inflammatory
cytokines associated with fatigue have been found to be elevated over a long period of time in
cancer survivors (Bower, 2014; Bower, Ganz, Aziz, & Fahey, 2002; Collado-Hidalgo et al.,
2006), which suggests that polymorphic (C) individuals may experience less fatigue than those
with wild-type (G).
A study by Collado-Hidalgo et al. (2006) assessed the relationship between ex vivo proinflammatory cytokine production and fatigue status among early state BCS. Fatigue status was
determined using the vitality scale of the SF-36 (score range 0-100, with higher scores indicating
well-being) and participants were deemed persistently fatigued if their scores were 50 or less
over two to three time points. Participants with scores greater than 70 were deemed non-fatigued
and included in the control group. The investigators found that persistently fatigued (N = 32)
BCS had increased ex vivo monocyte production of IL6 in versus non-fatigued (N = 19)
following exposure to lipopolysaccharide stimulation (p = .049).
A more recent study by Collado-Hidalgo et al. (2008) studied single nucleotide
polymorphisms in the promoter regions of genes associated with pro-inflammatory cytokines IL-
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6 and IL1B and their expressions, to assess their relationships with fatigue status in BCS.
Participants were screened for fatigue using the SF-36 vitality scale (score range 0-100, with
higher scores indicating well-being) and women with scores of 50 or less were deemed fatigued
and placed in the experimental group (N = 33) while women with scores of 70 or higher were
placed in the non-fatigued control group (N = 14). The Multidimensional Fatigue Symptom
Inventory was then used to confirm fatigue symptoms. The investigators extracted genomic
DNA from peripheral blood leukocytes and amplified by polymerase chain reaction technique
and genotypes were analyzed using chi-square and multivariate logistic regression analyses.
Results showed that homozygosity for either GG or CC variant of the IL6 −174 genotype
(p = .027) predicted fatigue.
A study by Bower et al. (2013) on variations in genes responsible for cytokine
production and fatigue among 171 BCS found statistically significant associations between
genetic risk scores involving SNP rs1800795 in IL6 gene and fatigue severity. Fatigue was
measured using the Multidimensional Fatigue Symptom Inventory (Short Form). The authors
hypothesized that polymorphisms in pro-inflammatory cytokine genes regulate expression and
therefore predict fatigue severity in BCS after the completion of cancer treatment. They found
that genetic risk score was significantly associated with fatigue (p = .002) with a small to
medium effect size (r = 0.22). Subjects possessing the GG genotype reported higher levels of
fatigue than those possessing the GC or CC genotype.
A study by Jim et al. (2012) on genetic predictors of fatigue in 53 prostate cancer
patients, it was found that those possessing the GC or CC genotype of SNP rs1800795 of IL6
gene reported increased fatigue intrusiveness, frequency, and duration than those possessing the
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GG genotype (p < .05). In their study, fatigue was assessed using the Fatigue Symptom
Inventory and DNA were genotyped via PCR analysis.
In a prospective, cross-sectional study by Shi et al. (2014) on the association between
SNP rs1800795 in IL6 and risk of persistent symptom burden in multiple myeloma patients,
patients rated the severity of 13 cancer-related symptoms from the MD Anderson Symptom
Inventory (MDASI) and their DNA were genotyped using PCR analysis. Of the 344 patients
included in the analysis, the two most commonly reported physical symptoms included fatigue
(47%) and pain (42%). For non-Hispanic whites, which comprised most of the sample (n = 222),
GG genotype predicted less severe fatigue (OR, 0.53; 95% CI, 0.29-0.88; p = .013) and in other
ethnicities, GG genotype predicted more severe pain (OR, 3.36; 95% CI, 1.23-13.64; p = .010).
In summary, alterations in COMT activity as well as circulating levels of IL1B and IL6
have been previously found in the literature to affect pain and fatigue symptoms in cancer
survivors. Variations in genotypes among genes associated with COMT, IL1B, and IL6
production have also been found to influence pain and fatigue reported by cancer survivors. The
findings have been mixed, which warrants further investigation of specific genotypes that may
moderate symptoms in these populations.
Mind-body interventions and their impact on pain and fatigue in BCS. Multiple
mind-body interventions exist in the literature for management of pain and fatigue symptoms
that BCS experience after curative treatment. In 2017, the American Cancer Society updated
clinical practice guidelines set forth by The Society for Integrative Oncology in 2014, for
integrative treatments during and after breast cancer treatment (Greenlee et al., 2017), and the
recommended mind-body therapies for the post-treatment management of fatigue and pain are as
follows:
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1. Acupuncture and yoga can be considered for improving post-treatment fatigue (Grade C
Recommendation).
2. Acupuncture, healing touch, hypnosis, and music therapy can be considered for the
management of pain (Grade C Recommendation).
Additional mind-body therapies that have been found effective for reducing fatigue in
cancer include Mindfulness-Based Stress Reduction (MBSR) (Carlson & Garland, 2005), the
Mindfulness-Based Stress Reduction for Breast Cancer program (MBSR(BC)) (Lengacher et al.,
2009, 2011, 2015a,b,c, 2016; Reich et al., 2017a), meditation (Dobos et al., 2015), yoga (Bower
et al., 2011), tai chi (Galantino et al., 2003; Larkey, Huberty, Pedersen, & Weihs, 2016; Rausch,
Robins, Walter, & McCain, 2006; Mustian et al., 2004), acupressure (Rosenberg, 2016), and
acupuncture (Dean-Clower et al., 2010).
Mind-body therapies that have been found effective for reducing pain in cancer include
acupressure (Yeh et al., 2017), acupuncture (Tao et al., 2016; Yang et al., 2017), hypnosis
(Montgomery et al., 2007, 2002), yoga and tai chi (Yang et al., 2017), healing touch (Post-White
et al., 2003; FitzHenry et al., 2014), music therapy (Binns-Turner, Wilson, Pryor, Boyd, &
Prickett, 2011; Li, Zhou, Yan, Wang, & Zhang, 2012), meditation (Dobos et al., 2015),
Mindfulness-Based Stress Reduction (Johns et al., 2016), and Mindfulness-Based Stress
Reduction for Breast Cancer (Kvillemo & Branstrom, 2011).
Mindfulness-based stress reduction (MBSR). Since its development at the University of
Massachusetts Medical Center by Dr. Jon Kabat-Zinn in the 1970’s, MBSR has become an
increasingly popular therapy to assist patients with a wide variety of conditions (Kabat-Zinn,
1985, 1994). The goal of MBSR is to “maintain awareness moment by moment, disengaging
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oneself from strong attachment to beliefs, thoughts, or emotions and thereby developing a greater
sense of emotional balance and well-being” (Ludwig & Kabat-Zinn, 2008, p. 1350).
Studies have proven mindfulness-based stress reduction as an effective therapy for BCS
experiencing adverse symptoms after cancer treatment ends. A study by Lengacher et al. (2016)
found that a 6-week Mindfulness-Based Stress Reduction for Breast Cancer program improved a
broad variety of symptoms in their randomized controlled trial of 322 BCS. Compared to UC,
those who received the intervention demonstrated improvement in both psychological symptoms
of anxiety and fear of recurrence, and physical symptoms including fatigue severity and fatigue
interference (p < .01). It was also found that the largest effect sizes included those for fear of
recurrence (d = 0.35) and fatigue severity (d = 0.27).
Lengacher et al.’s (2014) randomized controlled trial of 82 BCS who were randomly
assigned 1:1 to either a six-week MBSR(BC) program (N = 40) or control group (N =42)
reported that participants who received the intervention experienced favorable changes in the
symptoms they experienced after breast cancer treatment. Improvements were found among five
potential mediators: (1) the change in fear of recurrence mediated the effect of MBSR(BC) on
the six-week change in perceived stress (z = 2.12, p = 0.03) and state anxiety
(z = 2.03, p = 0.04); and (2) the change in physical functioning mediated the effect of
MBSR(BC) on the six-week change in perceived stress (z = 2.27, p = 0.02) and trait anxiety
(z = 1.98, p = 0.05).
In a randomized controlled pilot study by Johns et al. (2014) on MBSR for persistently
fatigued cancer survivors, 37 participants were randomly assigned in a 1:1 ratio to either a sevenweek MBSR program or a waitlisted control group and were followed for six months postintervention. Cancer survivors who received the MBSR intervention reported greater reductions
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in fatigue interference (d = -1.43, p < 0.001) and fatigue severity (d = -1.55, p < 0.001) than the
control group, which were assessed at baseline, post-intervention, one-month follow-up, and sixmonth follow-up using the Fatigue Symptom Inventory.
Research has also focused on not only MBSR itself, but also how it compares to other
interventions aimed at treating adverse symptoms after cancer treatment. In a study by Johns et
al. (2016,a) of 71 breast and colorectal cancer survivors comparing MBSR to psychoeducational
support, the authors did not find a significant improvement in cancer-related fatigue after the
intervention, however, they did report a trend favoring MBSR (p = 0.073) at one time point.
They also reported a significant effect size in vitality (p = 0.003) at the same time point. The
group who received MBSR also reported higher satisfaction with their intervention than the
psychoeducational support group (M=8.7 and M=8.4, respectively).
A meta-analysis by Huang, He, Wang, and Zhou (2016) of 964 BCS in nine articles
reported that compared to control groups, those who receive mindfulness-based stress reduction
have statistically significant improvements in depression, anxiety, and stress (p’s < 0.00001) and
increased quality of life (p = 0.03).
Mindfulness-based stress reduction has also been found to have a positive effect on sleep,
as evidenced by a randomized controlled trial by Lengacher et al. (2015c) in BCS. In their study,
79 participants were randomly assigned to either the intervention group (MBSR(BC)) or UC.
Using subjective sleep assessments, such as a sleep diary and the Pittsburgh Sleep Quality Index,
and objective sleep assessments, such as actigraphy, it was indicated that the MBSR(BC)
program had greater positive effects on objective sleep parameters involving sleep efficiency (p
= 0.04), time spent sleeping (p = 0.02), and less waking periods (p < 0.01), than the UC group at
a 12-week follow-up after the intervention.
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Mindfulness-based stress reduction has also been found to be effective in treating
symptom clusters, defined as multiple concurrent and related symptoms “that are not required to
have a shared etiology” (Dodd, Miaskowski, & Paul, 2001, p.465). In Lengacher et al.’s (2012)
study of symptom clusters in 322 BCS, results indicated that mindfulness-based stress reduction
modestly improved fatigue and sleep disturbances. Further, Reich et al.’s (2017a) study of
immediate and sustained effects of the Mindfulness-Based Stress Reduction for Breast Cancer
program found that mindfulness-based stress reduction improved clusters of symptoms in BCS at
the six-week assessments, particularly for fatigue and psychological clusters, showing immediate
effects.
Mindfulness-Based Stress Reduction has been found to be a cost-effective and therapy
for BCS. In a study by Lengacher et al. (2015a), the authors noted that cost for increased quality
of life per year was relatively low compared to other breast cancer interventions found in the
literature. Mindfulness-Based Stress Reduction has been adapted to a mobile intervention for
BCS, to provide an at-home accessible solution to those who find it difficult to travel.
Mindfulness-based stress reduction has also been found to be an accessible therapy for
BCS. In a pilot study by Lengacher et al. (2017), a six-week Mindfulness-Based Stress
Reduction for Breast Cancer program was adapted to mobile delivery of the intervention among
15 participants. Thirteen participants completed the study and the results showed that there were
significant improvements in both psychological (depression, anxiety, stress, fear of recurrence)
and physical symptoms (sleep quality and fatigue) and quality of life (p's < 0.05).
It has been shown that Mindfulness-Based Stress Reduction may also improve immune
recovery during breast cancer management, as evidenced by four studies found in the literature.
A randomized controlled trial of 82 breast cancer patients was conducted by Lengacher et al.
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(2013). Participants were randomized to either a mindfulness-based stress reduction or control
group. Immunological biomarkers were analyzed at baseline and within two weeks postintervention and it was found that women who received the intervention experienced a faster
recovery of functional T cells.
In addition, Reich et al. (2014) also found a positive relationship between immune
recovery markers and Mindfulness-Based Stress Reduction, with a regression model that found
predictors of gastrointestinal improvement included B-lymphocytes and interferon-γ as the (p <
.01), predictors of cognitive and psychological improvements included +CD4+CD8 (p = .02),
and predictors of fatigue symptom improvement included lymphocytes and IL-4 (p < .01).
Another study by Reich et al. (2017b) of 322 BCS found that a Mindfulness-Based Stress
Reduction for Breast Cancer program affected cytokine levels, particularly in increasing levels of
TNFa and IL-6, markers of immune recovery. At baseline of the study, it was found that IL6
cytokine levels varied according to type of cancer treatment, and negative correlations were
found between patients who received mastectomy (versus lumpectomy) and chemotherapy,
meaning they experienced lower levels of IL6 (p < .05). Participants who had received radiation
experienced higher levels of IL6 (p < .01). Compared to control group participants, patients in
the MBSR(BC) intervention group experienced higher increases in plasma levels of IL6 (p = .05)
over the 12-week period of the study, versus the control group. It was suggested that MBSR(BC)
supports immune system restoration in BCS.
Lastly, another randomized controlled trial by Sarenmalm, Martensson, Andersson,
Karlsson, and Bergh (2017) on the effects of Mindfulness-Based Stress Reduction on immune
function in 177 BCS, it was found that natural killer cell activity (p = 0.015) and CD3+T and
CD3+8+T-lymphocyte activity shifted (p = 0.027 and p = 0.035, respectively), in which the
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authors suggested that this biological response was consistent with study by Fang et al. (2010),
showing that increased post-Mindfulness-Based Stress Reduction well-being was associated with
a shift in natural killer activity.
Mindfulness-Based Stress Reduction has recently entered into the personalized medicine
arena, with genetic a study by Lengacher et al. (2015b) on cognitive impairment and
MBSR(BC). Their two-armed randomized controlled trial tested whether 10 SNPs in eight genes
known to be associated with cognitive function were associated with cognitive impairment in
their sample of 72 participants, and if the SNPs moderated the effects of the Mindfulness-Based
Stress Reduction for Breast Cancer program on cognitive impairment, versus a UC group.
Participants (mean age 58 years) were randomized 1:1 to either a six-week MBSR(BC) program
or UC and cognitive impairment was assessed at baseline, six weeks, and 12 weeks, using the
Everyday Cognition (ECog) questionnaire. The ECog is a 40-item self-report questionnaire that
asks patients to compare everyday functioning on a 4-point scale at the present moment versus
10 years ago (1 = better or no change, to 4 = consistently much worse). DNA samples extracted
from their blood were used to genotype using TaqMan allele discrimination polymerase chain
reaction (PCR). The results showed that SNPs in four genes (ANKK1, APOE, MTHFR, SLC6A4)
were associated with cognitive impairment. In addition, a single nucleotide polymorphism,
rs1800497 in gene ANKK1, moderated the effects of the Mindfulness-Based Stress Reduction for
Breast Cancer program on cognitive impairment. Specifically, participants carrying the
polymorphic AA or AG genotype received more benefit than those carrying the wild-type (GG)
genotype. To this date, there are currently no studies examining patient outcomes involving
genetic influence on pain and fatigue symptom improvement resulting from MBSR(BC).
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Research has shown MBSR(BC) as a mind-body therapy that has been proven to be
effective for treating individual symptoms experienced by BCS, including anxiety, depression,
stress, fatigue, and sleep, as well as symptoms that occur in clusters and cognitive impairment. It
has been found in the literature that MBSR affects biomarkers including circulating cytokines,
and has recently entered the realm of precision medicine with a study that found genetic
moderation of cognitive impairment in BCS participating in a MBSR(BC) program.
Summary
In summary, fatigue and pain are commonly reported by BCS. Findings from the
literature identify fatigue and pain as highly prevalent among BCS, which negatively affects their
quality of life and the ability to function in everyday activities. Fatigue and pain symptoms have
been associated with biomarkers in the body, including pro- and anti-inflammatory cytokines
such as IL1B and IL6, and the enzyme COMT, in which genes associated in their pathways are
under investigation in this study. Previous research found in this review of literature has
identified associations between pain and fatigue symptoms and genetic variations in subjects
experiencing such symptoms. Mind-body interventions such as MBSR(BC) have been proven
effective at treating multiple symptoms experienced by BCS and has recently entered the
precision medicine arena.
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Chapter Three
Methods
Introduction
Chapter three explains the methods and procedures for this study. The purpose of this
study was to identify specific genotypes involved in fatigue and pain symptoms and explore
whether SNP rs16944 in gene IL1B, SNP rs4680 in gene COMT, and SNP rs1800795 in gene IL6
moderate fatigue and/or pain outcomes in BCS and whether the effects of the MBSR(BC)
intervention on fatigue and/or pain are moderated by these SNPs. This chapter first provides
detailed information regarding the research design, setting, and sample for this genetic research,
which was conducted within the R01 MBSR Symptom Cluster Trial for Breast Cancer Survivors.
Next, the instruments used to measure each outcome variable will be detailed, followed by the
procedures and data analyses used.
Research Design
This research study was partially funded by a grant awarded by Sigma Theta Tau
International Honor Society of Nursing, Delta Beta-at-Large chapter and was conducted in part
as a secondary data analysis within the parent study, MBSR Symptom Cluster Trial for Breast
Cancer Survivors/ R01CA131080. This parent R01 study used a two-group randomized design,
with 1:1 ratio assignment of BCS to either: (1) a six-week MBSR(BC) program, or (2) Usual
Care (Figure 1). Randomization was stratified by: (1) type of breast cancer surgery (lumpectomy
vs. mastectomy); (2) breast cancer treatment (chemotherapy with or without radiation vs.
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radiation alone); and (3) stage of cancer at diagnosis (0-III). The current study implemented
additional analyses of stored biological DNA samples and physical symptom measurement data
to explore pain and fatigue outcomes resulting from the MBSR(BC) intervention and their
possible genetic moderating effects.
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Figure 2. Consolidated Standards of Reporting Trials (CONSORT) flow diagram of participant
screening, enrollment and allocation from parent R01 trial to study subset.
Setting. Participants were recruited from the Carol and Frank Morsani Center for
Advanced Health as well as Moffitt Cancer Center, both located in Tampa, Florida. The
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assessments and delivery of the intervention took place at the Survivorship Clinic of the Moffitt
Cancer Center and Research Institute. Genotyping was performed at the laboratory of Dr. Jong
Park at Moffitt Cancer Center and Research Institute.
Population and Sample. The primary inclusion criteria for this study were: 1) women
age 21 or older who had been diagnosed with stage 0-III BC who had undergone lumpectomy
and/or mastectomy, 2) were at least two weeks but no more than two years from end of cancer
treatment with adjuvant radiation and/or chemotherapy. Exclusion criteria included: 1) patients
diagnosed with stage IV BC, 2) self-reported a severe current psychiatric diagnosis (e.g. bipolar
disorder), or 3) recurrent BC. Out of 322 women who participated in the parent R01 Symptom
Cluster Trial for Breast Cancer Survivors study, 158 (MBSR(BC) = 75; UC = 83) consented for
genetic study with their DNA, and were included in this study.
Measurements
Demographic survey. Demographic data were collected from participants and included
age, sex, gender, race, ethnicity, marital status, income status, highest level of education
completed, and employment status (see Appendix A). Demographic data were gathered at
baseline and updated at six and 12 weeks. A chart audit was completed through use of medical
records to verify all medical and treatment information.
Clinical history survey. A Standard Clinical History form was collected at baseline and
updated at six and 12 weeks to determine if there were any new problems and treatment related
to problems. Data collected included types of cancer treatment, medications, stage of cancer
diagnosis, date treatment ended.
Brief Pain Inventory. Pain was measured by the Brief Pain Inventory (BPI), which was
developed to assess pain related to cancer and gives patients the ability to rate their pain severity
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and the extent to which it interferes with dimensions of feeling and ability to function (Cleeland,
2009). The BPI (see Appendix B) contains 9-items that examine pain intensity and interference
in patients (Keller et al., 2004). Items 1-6 assess pain type, pain location, and pain severity
during the past week, on average and at present. Items 7-8 refer to medications and their
usefulness in relieving pain. Item 9 assesses the severity of pain interference in patients’ daily
activities. Reliability coefficients for the BPI Severity and Interference scales were high with
reliability coefficients ranging from .82 to .95.
Fatigue Symptom Inventory. Fatigue was measured by the Fatigue Symptom Inventory
(FSI). The FSI (see Appendix C) is a 14-item self-report measure designed to assess fatigue
severity, its frequency, and its daily pattern (Hann et al., 1998; Hann, Deniston, & Baker, 2000;
Stein & Jacobsen, 1998). Items include 4 indicators of fatigue experienced in the past week and
are measured on separate 11-point scales (0=Not at all fatigue; 10=Extreme fatigue) as well as
current fatigue. Perceived interference is a seven-item subscale that uses separate 11-point scales
to assess fatigue’s interference with daily activities and was found to have good internal
consistency with alpha coefficients ranging from 0.93-0.95 (Radiation Therapy Oncology Group,
2010). Convergent validity was demonstrated by significant positive correlations measures
between the FSI and (POMS-Fatigue Scale) and significant negative correlations between the
FSI and measures of psychological functioning (e.g., SF-36 Health Survey). Reliability
coefficients for the FSI were high at >.90.
Candidate gene and single nucleotide polymorphism selection. Candidate genes and
SNPs were chosen to represent polymorphisms in genes involved in various pathways, including
fatigue and pain function using PubMed database. Selected genes examined in these pathways
include COMT, IL1B, and IL6. Once candidate genes were confirmed, SNPs were selected based
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on their previous associations with gene transcription or protein activity related to pain via
COMT (Barbosa et al., 2012; Fijal, Perlis, Heinloth, & Houston, 2010; Finan et al., 2011;
Jacobsen et al., 2012; Kim et al., 2006; Omair et al., 2012; Martinez-Jauand et al., 2013; Nicholl
et al., 2010; Rakvag et al., 2008; Smith et al., 2014; Tammimaki & Mannisto, 2012; VargasAlarcon et al., 2007; Wang et al., 2015; Zubieta et al., 2003) and IL6 (Branford, Droney, & Ross,
2012; Kovacs et al., 2016; Reyes-Gibby et al., 2008), and fatigue via IL1B (Bower et al., 2013;
Jim et al., 2012; Reinertsen et al., 2011).
Procedures
Approvals. This study was approved by the University of South Florida Institutional
Review Board and Scientific Review Committee for Moffitt Cancer Center
(IRB #Ame12_107408) (see Appendix D). All policies for the University of South Florida
Institutional Review Board and Scientific Review Committee for Moffitt Cancer Center were
adhered to.
Recruitment. Potential participants who met the inclusion criteria were recruited from
the breast cancer treatment center clinics at the Moffitt Cancer Center and Research Institute and
USF’s Carol and Frank Morsani Center for Advanced Healthcare. Health practitioners were
provided with a complete description of the study aims and protocol. Consistent with current
HIPAA regulations, patients were contacted by Moffitt members and health practitioners who
identified eligible patients during routine patient care, and they provided a brief overview of the
MBSR(BC) study. Multiple recruitment methods were used. To maintain consistency in
participant recruitment, the recruiters followed a template to describe the study. Second,
advertisements were placed in Moffitt Cancer Center and Research Institute, which included
flyers and brochures. A log was implemented to track contacts made between the study recruiters
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and potential participants. Interested patients who met the study inclusion criteria were asked to
sign a form to show their interest in participating in the study.
Informed consent. Patients who were interested in the study were invited to an in-person
orientation session, in which the principal investigator or the research assistant explained the
details of the study and requirements to participate and combined HIPAA and consent
documents were obtained. To maximize enrollment and minimize patient dropout, the principal
investigator emphasized that, regardless of random assignment, all participants would be able to
participate in the MBSR(BC) program and if they were assigned to UC, the program would be
available following a wait period. Moreover, it was emphasized that the timing of the
intervention was selected to assist in the critical transition period when formal medical care and
support had ended, which was at least two weeks but not more than two years after cancer
treatment ended. Details of the study were reviewed with the patients, including the six-week
schedule of the MBSR(BC) program, information about the blood draw, and the three time
points for the questionnaires to be completed. Consent was obtained from all study participants.
Data collection procedures. An in-person collection of demographic data, clinical
history data, the Fatigue Symptom Inventory, and Brief Pain Inventory, were performed at
baseline, the end of the six-week intervention, and follow-up at 12 weeks, which were collected
from all participants who agreed to participate in the study. Five milliliters of blood were drawn
at baseline from the 158 participants who consented for genetic analyses and were part of this
study. Genomic DNA were isolated from peripheral blood leukocytes with a Qiagen DNA
extraction kit (Qiagen, Valencia, CA) with modifications, and stored at Dr. Jong Park’s
laboratory at Moffitt Cancer Center and Research Institute. For this dissertation study,
genotyping was performed using the stored DNA. A total of three candidate SNPs in three genes
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(rs1800795 in IL6, rs16944 in IL1B, rs4680 in COMT) were found to be associated with fatigue
and pain symptoms during a literature review and a preliminary study (Lengacher et al., 2015b).
DNA samples from blood were genotyped using TaqMan allele discrimination PCR analysis
method. Different probes were used in the PCR analysis to determine between variant DNA
sequences at a single locus. In short, PCR reactions were performed using both 96-well and 384well plates on separate occasions. The 96-well plates were prepared by combining 10µL TaqMan
Universal PCR Master Mix, 0.5µL primer, 5.5µL RNA-free water, and 4µL DNA, for a total of
20µL per well. The 384-well plates were prepared by combining 5µL TaqMan Universal PCR
Master Mix, 0.25µL primer, 2.75µL RNA-free water, and 2µL DNA, for a total of 10µL per
well. PCR was performed for 45 amplification cycles using the ABI Prism 7900HT. Sequence
Detection System (SDS) version 2.3 was used to distinguish between wild-type and polymorphic
alleles by identifying homozygous wild-type, homozygous variant, or heterozygous genotype
alleles. Assays included two controls and five duplicates as part of quality control.
Description of intervention. The MBSR(BC) program is a six-week complementary
alternative medicine program adapted and tested by Lengacher et al. (2009) from Dr. Jon KabatZinn’s original eight-week program aimed at reducing stress through self-regulation of
symptoms to improve the quality of life in BCS (Lengacher et al., 2009). The intervention
components consist of: 1) educational material, 2) formal and informal meditative practice
techniques, and 3) group processes related to barriers to the practice of meditation and the
application of mindfulness in daily situations (Lengacher et al., 2009). Participants received
training in four types of meditation techniques including: 1) sitting meditation, 2) body scan, 3)
Gentle Hatha Yoga, and 4) walking meditation. Subjects assigned to the MBSR(BC) group were
scheduled for six weekly sessions lasting two hours each, which were conducted by a group
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leader trained in MBSR(BC). Class sizes consisted of five to six participants. In addition to the
repeated assessment of blood studies and psychological symptoms, physical symptoms, quality
of life and mediators at 6 and 12 weeks. MBSR(BC) participants were also asked to record their
formal meditation practice times in a daily diary during the intervention period as well as during
the following six-week period after the end of the intervention.
The UC group consisted of standard post-treatment follow-up clinic visits and
participants were asked to abstain from meditation or yoga techniques. Usual care participants
were waitlisted to the MBSR(BC) intervention, giving them the ability to participate in the
MBSR(BC) program after study end (after 12 weeks).
Data management. The statistical software used for data entry, management, and
analysis was Statistical Package for Social Sciences (SPSS) version 25. All data were deidentified and in order to maintain patients’ confidentiality, password-protected files were stored
in Dr. Cecile Lengacher’s office, the principle investigator of the parent study.
Data Analysis
Sample characteristics were analyzed using descriptive statistics and frequency
distributions generated from SPSS. Chi-Square tests were used for categorical variables and ttests were used for continuous variables, to identify any potential differences between groups not
controlled for by randomization.
Aim #1: To identify specific genotypes involved in fatigue and pain symptoms.
First, to identify specific genotypes that are significantly associated with fatigue and/or pain
symptoms at baseline, a one-way linear trend ANOVA was performed in SPSS for each SNP.
Aim #2: To explore whether single nucleotide polymorphism (SNP) rs1800795 in gene
IL6, SNP rs16944 in gene IL1B, and SNP rs4680 in gene COMT, moderate the effects of the
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MBSR(BC) intervention on fatigue and/or pain symptoms, a comparison of mean scores on
Fatigue Symptom Inventory and Brief Pain Inventory subscales over time at three time points
(baseline, 6 weeks, 12 weeks) for each SNP were first examined. A mixed model (MBSR(BC) X
time) approach was then performed. Single nucleotide polymorphism variables and MBSR(BC)
were analyzed as main effects along with the interaction of MBSR(BC) x SNP and MBSR(BC) x
SNP x time (baseline to 12 weeks). A statistically significant interaction between MBSR(BC) x
SNP on the slope of symptom change indicates that the relationship between MBSR(BC) and
symptoms varies as a function of SNPs. Because we proposed to test a specific intervention
(MBSR(BC)) and multiple SNPs in genes with multiple outcomes, a false discovery rate (FDR)
approach was used. Given the potential for multiple comparisons of three SNPs in three genes
associated with pain and fatigue from a literature review, an FDR rate of 0.10 was adopted. This
value means that 10% of the rejected null hypotheses were assumed to be type 1 errors
(Benjamini & Hochberg, 1995).
Statistical power. Since the sample size among different races may lack precision, the
analyses were limited to Caucasians due to the insufficient number of minorities. A sample size
of 158 subjects provides 80% power with 2-sided type I error rate of 0.05 to detect an effect size
of 1.2 for the two-way interactions between genotype x time, genotype x assignment
(MBSR(BC) versus UC), and assignment x time, analyzed in SPSS using linear mixed models
from Aim 2. As these analyses were not designed to be confirmatory, no correction procedure
was used for the type I error rate.
Methodological issues and limitations. Due to the modest sample size of 158 patients
(MBSR(BC) n = 75; UC n = 83), the identification of SNPS associated with fatigue and/or pain
symptoms and the degree to which they potentially moderate the effects of the MBSR(BC)
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program may be subject to uncertainty. However, for Aims 1 and 2, the analysis should not be
considered confirmatory, but rather as providing insight into the extent to which specific SNPs
may modify the effectiveness of the MBSR(BC) program in reducing levels of pain and fatigue.
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Chapter Four
Results
Introduction
This chapter presents the results of the study. First the descriptive characteristics of the
sample are presented, followed by the study findings for Aim 1 and Aim 2 identifying specific
genotypes associated with fatigue and pain outcomes after breast cancer treatment and exploring
whether specific genotypes moderated the effects of MBSR(BC) on fatigue and pain outcomes.
Participant Characteristics
The sample consisted of 158 BCS from the original 322 BCS enrolled in the R01
Symptoms Cluster Trial for Breast Cancer Survivors/1R01CA131080, for which DNA had been
collected. Participants were enrolled into the study and were randomly assigned to either the
MBSR(BC) or UC group using computer-generated randomization, which randomly assigned
participants stratified by stage of cancer (Stages 0-III) and type of cancer treatment (lumpectomy
versus mastectomy and radiation with or without chemotherapy). Among the 158 participants,
there were no significant differences in age, stage of cancer, or type of cancer treatment, between
the MBSR(BC) (n = 75) and UC (n = 83) groups. However, there were significantly more (p =
.04) participants in the UC group (83.1%) within one year from end of cancer treatment
compared to the MBSR(BC) group (69.3%) (see Table 3).
Baseline demographic comparisons were produced for all 158 participants. Furthermore,
fatigue and pain symptom data were complete for all 158 participants at baseline, six weeks, and
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the 12-week follow-up. All 158 participants completed the study data points. Baseline
demographics are illustrated in Table 1. Chi-Square tests were used for categorical variables and
t-tests were used for continuous variables (i.e. age), to identify any potential differences between
groups not controlled for by randomization.
The mean age for the total sample was 58.4 years, with the mean age for the MBSR(BC)
group being 58 years and 58.7 years for the UC group. The majority of participants were white,
non-Hispanic (89%), and differences between groups were similar, with the MBSR(BC) group
being 89% White, non-Hispanic and the UC group being 88% white, non-Hispanic. There were
no significant differences (p > .05) between the MBSR(BC) and UC groups on any of the
demographic characteristics for age and race/ethnicity. The majority (70.9%, n=112) of
participants in the sample were married and this was similar between groups, with 72% (n=54) of
participants being married in the MBSR(BC) group, and 69.9% (n=58) being married in the UC
group. The total sample’s education status was mostly college educated, with 75.3% at least
having some college education or an associate’s degree. Approximately two-thirds of the
participants were unemployed (n=100, or 63.3%), while approximately one-third (n=58, or
36.7%) were working either part time (<32 hours per week) or full time (>32 hours per week).
Among the MBSR(BC) group, 33.3% (n=25) were employed, while 39.8% (n=33) of the UC
group were employed. Finally, the majority of the sample included those with an annual
household income of $40,000 to less than $80,000 (29.1%), and there were no statistically
significant differences (p = .905) between groups for annual household income. Three subjects
declined to report their income, for a total of 2% missing values.
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Table 1. Baseline Demographics (Age, Race/Ethnicity, Marital Status, Education Status,
Employment Status, and Annual Household Income of Participants) By Randomization
Assignment by Frequency and Percent
Variable
Total
MBSR(BC)
Usual Care
p value
N=158
n=75
n=83
Mean Age + Standard Deviation 58.4±9
(years)
Race, Ethnicity
White, non-Hispanic
White, Hispanic
Marital Status, n (%)
Married
Divorced
Single
Widowed
Other

58±10

58.7±8

67 (89%)
8 (11%)

73 (88%)
10 (12%)

.948
140 (89%)
18 (11%)

.805
112 (70.9%)
5 (3.2%)
16 (10.1%)
21 (13.3%)
4 (2.5%)

54 (72%)
2 (2.7%)
7 (9.3%)
9 (12%)
3 (4%)

58 (69.9%)
3 (3.6%)
9 (10.8%)
12 (14.4%)
1 (1.3%)

Education Status, n (%)
No College
Some Grade School
Some High School
High School Graduate
Vocational/Technical School
Some College
College
Graduate or Professional School

1 (0.6%)
3 (1.9%)
26 (16.5%)
9 (5.7%)
45 (28.5%)
41 (25.9%)
33 (20.9%)

1 (1.3%)
2 (2.7%)
11 (14.7%)
4 (5.3%)
19 (25.3%)
20 (26.7%)
18 (24%)

0 (0%)
1 (1.3%)
15 (18.1%)
5 (6%)
26 (31.3%)
21 (25.3%)
15 (18.1%)

Employment Status, n (%)
Employed
Unemployed

58 (36.7%) 25 (33.3%)
100 (63.3%) 50 (66.7%)

33 (39.8%)
50 (60.2%)

Annual Household Income, n
(%)
<$10,000
$10,000 to $19,999
$20,000 to $39,999
$40,000 to $79,999
$80,000 to $99,999
>$100,000
Declined to Report

.904

.803

.812

.905
19 (12%)
25 (15.8%)
31 (19.6%)
46 (29.1%)
13 (8.2%)
21 (13.3%)
3 (2%)

9 (12%)
13 (17.3%)
12 (16%)
24 (32%)
6 (8%)
10 (13.3%)
1 (1.4%)

46

10 (12%)
12 (14.4%)
19 (22.9%)
22 (26.5%)
7 (8.4%)
11 (13.3%)
2 (2.5%)

The results related to clinical characteristics (stage of disease, surgery type, treatment
type, and time since treatment) for the participants in the total sample, as well as comparisons of
the MBSR(BC) and UC groups, are displayed in Table 2. Cancer staging for the total sample
included Stage 0, n=18 (11.4 %); Stage I, n=61 (38.6 %); Stage II, n=54 (34.2 %); and Stage III,
n=25 (15.8 %). There were no statistically significant differences (p = .67) between groups. The
treatment breakdown included 13.9% (n=22) of total sample participants having chemotherapy
only, 25.9% (n=41) had radiation only, 30.4% (n=48) had a combination of chemotherapy and
radiation, and 29.7% (n=47) had no chemotherapy or radiation. There was no statistically
significant difference (p=.905) between the MBSR(BC) and UC groups for cancer treatment. The
majority of total sample participants were treated surgically by mastectomy (n=93, or 58.9%)
versus lumpectomy (n=65, or 41.1%). There was similarity between groups, with 61.5% (n=51)
of UC and 56% (n=42) of MBSR(BC) participants treated by mastectomy and 38.5% (n=32) of
UC and 44% (n=33) of MBSR(BC) participants treated by lumpectomy there was no statistically
significant difference between groups (p = .487). Descriptive frequencies showed that for the
total sample, 64.6 % (n= 102) of participants had been treated with hormone therapy, which
included single or combination medications such as anastrazole, letrozole, levothyroxine,
tamoxifen, Herceptin, or other hormone medications. There was no statistically significant
difference (p = .233) between MBSR(BC) or UC groups for hormone therapy. At the baseline
time point of this study, it had been less than one year for most (n=121, or 76.6%) participants
since the end of cancer treatment. There was a statistically significant difference (p=.041)
between the MBSR(BC) and UC groups for time since treatment. Between groups, nearly twice
as many of the MBSR(BC) group participants (n=23, or 30.7%) were more than one year since
cancer treatment end, versus the UC group participants (n=14, or 16.9%).
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Table 2. Clinical History Data (Stage of Disease, Surgery Type, Treatment Type, and Time Since
Treatment) for Participants by Randomization Assignment by Frequency and Percent
Variable
Total
MBSR(BC)
Usual Care
p value
N=158
n=75
n=83
Cancer Stage, n (%)
.670
0
18 (11.4%) 7 (9.3%)
11 (13.3%)
I
61 (38.6%) 28 (37.3%)
33 (39.8%)
II
54 (34.2%) 29 (38.7%)
25 (30.1%)
III
25 (15.8%) 11 (14.7%)
14 (16.9%)
Surgery Type, n (%)
Lumpectomy
Mastectomy

65 (41.1%)
93 (58.9%)

33 (44%)
42 (56%)

32 (38.5%)
51 (61.5%)

Treatment Type, n (%)
Chemotherapy
Radiation
Chemotherapy and Radiation
No Chemo or Radiation

22 (13.9%)
41 (25.9%)
48 (30.4%)
47 (29.7%)

9 (12%)
19 (25.3%)
24 (32%)
23 (30.7%)

13 (15.7%)
22 (26.5%)
24 (28.9%)
24 (28.9%)

Hormonal Therapy Status, n (%)
Yes
No

102 (64.6%)
56 (35.4%)

23 (30.7%)
52 (69.3%)

33 (39.8%)
50 (60.2%)

Time Since Treatment, n (%)
<1 Year
1 to 2 Years

.487

.905

.233

.041
121 (76.6%)
37 (23.4%)

52 (69.3%)
23 (30.7%)

69 (83.1%)
14 (16.9%)

The demographic characteristics within this study’s subset (N = 158) were similar to
those found within the parent study. The average age among BCS in this study was 58.4 years,
versus 56.5 years among the 322 BCS in the parent study (Lengacher et al., 2016). Among BCS
in the parent study, 69.4% of participants were white, non-Hispanic, which is lower than in this
study’s sample (89%). This is due to the exclusion of other races and ethnicities, as the sample
size would not allow for genetic analyses among those groups. Most BCS were married in both
the parent study (64.4%) and this study (70.9%). Most BCS were college educated in both the
parent study (some college or above = 82.2%) and this study (some college or above = 75.3%),

48

and two-thirds were not working in both studies. A majority of BCS had an annual household
income of $40,000 to less than $80,000 in both the parent study (24.2%) and this study (29.1%).
The clinical characteristics within this study’s subset (N = 158) were also similar to those
found within the parent study. However, more patients were diagnosed with Stage II cancer in
the parent study (35.7%), whereas more patients were diagnosed with Stage I cancer in this
study’s subsample (38.6%). A majority of patients in both studies received mastectomy (parent
study, 53.4%; this study, 58.9%) versus lumpectomy and a combination of chemotherapy and
radiation (parent study, 35.7%; this study, 30.4%) versus other types of treatments. Finally, the
majority of patients were also on hormone treatment in both the parent study (55.9%) and this
study’s subsample (64.6%) as well.
In summary, randomization successfully controlled for most potential differences
between groups (MBSR(BC) and UC) in demographic and clinical history data characteristics.
However, the MBSR(BC) and UC groups were significantly different for time since treatment,
with more time since treatment (at least one year) for the MBSR(BC) group than the UC group.
Demographic and clinical characteristics were similar among BCS within the parent study and
this study’s subset.
Characteristics in Candidate SNPs
Prior to analysis of the associations of the SNPs (rs4680, rs16944, rs1800795) with pain
and fatigue outcomes, characteristics of the SNPs were identified and presented in Table 3. The
wild-type alleles for this sample were determined to be (A) for COMT SNP rs4680, (G) for IL1B
SNP rs16944, and (G) for IL6 SNP rs1800795. The minor allele frequency (MAF) for each SNP
was determined to be 0.46 for SNP rs4680, 0.32 for rs16944, and 0.38 for rs1800795. The
genotype distributions for the SNPs in this study were tested for and passed Hardy-Weinberg
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equilibrium, with no statistically significant differences (p’s > .05). Hardy-Weinberg equilibrium
suggests that if the general population have allele frequencies of a and b, the sample should have
allele frequencies of a2, 2ab, and b2. This method was used to reduce the likelihood of false
results from genotyping error.
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Table 3. Characteristics of Candidate SNPs
MAF

22/For

Allele
(P/W)
G/A

0.46

Poly/HT/WT
MBSR(BC) UC
(n = 75)
(n = 83)
13/38/24
21/38/24

2/For

A/G

0.32

10/38/27

4/35/44

rs1800795 7/For

C/G

0.38

11/36/28

10/41/32

Gene
SNP ID
Symbol
COMT rs4680

Chr/Or

IL1B

rs16944

IL6

HWE

Function

0.96
0.85

Missense Val158Met affects
dopamine levels in the brain (Stein et
al., 2006)
Affects plasma levels of IL1B

0.94

Affects plasma levels of IL6

Note. SNP = single nucleotide polymorphism; Chr = chromosome; Or = orientation; COMT = catechol-O-methyltransferase; IL1B =
interleukin 1, beta; IL6 = interleukin 6; Allele (P/W) = polymorphic/wild; MAF = minor allele frequency; Poly/HT/WT = homozygous
polymorphic/heterozygous polymorphic/wild; For = forward.
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Results Aim 1
The first aim of this study was to identify specific genotypes related to symptoms of
fatigue and pain. The hypothesis for this aim was that specific genotypes are associated with
higher or lower levels of pain and fatigue among BCS. To identify what specific genotypes of
the three candidate SNPs were significantly associated with fatigue and pain symptoms at
baseline, trend analyses using one-way linear ANOVAs were performed in SPSS among all
participants (MBSR(BC), N = 75; and UC, N = 83), but found no statistically significant
correlations (see Tables 4-6).
First, for SNP rs4680 in COMT gene, neither AA, AG, nor GG genotype were associated
with a difference in mean scores on fatigue severity, fatigue interference, pain severity, or pain
interference (see Table 4). For fatigue severity, there was no linear relationship among mean
scores from AA to AG to GG, with mean scores of 14.63, 14.33, and 15.59 respectively. For
fatigue interference, there was no linear relationship in mean scores as well, with mean scores of
27.17, 25.68, and 27.15 for AA, AG, and GG respectively. The same occurred for pain severity,
with no linear pattern for AA, AG, and GG with mean scores of 8.88, 8.63, and 9.32
respectively. Although genotype did follow a linear pattern for mean scores for pain interference,
with a consistent increase in mean scores from AA to GG (AA = 13.15; AG = 14.64; GG =
16.79), this was not statistically significant (p = .328).
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Table 4. One-Way ANOVA Linear Trend Analysis between SNP rs4680 in gene COMT and Pain
and Fatigue Scores
Symptom Outcome
Measure
Fatigue Severity

Genotype

Mean

SD

F

p-value

AA
AG
GG

14.63
14.33
15.59

8.06
8.16
7.77

.285

.594

AA
AG
GG

27.17
25.68
27.15

19.63
21.77
18.54

.000

.997

AA
AG
GG

8.88
8.63
9.32

8.27
8.21
8.22

.059

.808

Fatigue Interference

Pain Severity

Pain Interference
AA
13.15
14.53
.963
.328
AG
14.64
17.84
GG
16.79
16.38
Note. COMT = catechol-O-methyltransferase; SNP = single nucleotide polymorphism
Second, for SNP rs1800795 in gene IL6, neither CC, CG, or GG genotypes were
associated with a difference in mean scores on fatigue severity, fatigue interference, pain
severity, or pain interference (see Table 5). For fatigue severity, there was no linear relationship
among mean scores for CC, CG, and GG genotypes, with mean scores of 14.35, 14.22, and 15.42
respectively. For fatigue interference, there was no linear relationship in mean scores as well,
with mean scores of 24.67, 24.18, and 29.98 for CC, CG, and GG respectively. For pain severity,
there did appear to be a linear pattern among scores for CC, CG, and GG with mean scores of
8.81, 8.82, and 8.92 respectively, however, this was not significant (p = .959). The same
occurred for pain interference, with a linear increase in scores from CC to CG to GG, however,
this also was not significant (p = .506).
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Table 5. One-Way ANOVA Trend Analysis Between SNP rs1800795 in gene IL6 and Pain and
Fatigue Scores
Symptom Outcome
Measure
Fatigue Severity

Genotype

Mean

SD

F

p-value

CC
CG
GG

14.35
14.22
15.42

7.84
8.46
7.54

.274

.601

CC
CG
GG

24.67
24.18
29.98

19.06
20.19
20.84

1.067

.303

CC
CG
GG

8.81
8.82
8.92

8.17
8.76
7.54

.003

.959

.445

.506

Fatigue Interference

Pain Severity

Pain Interference
CC
13.14
15.20
CG
14.05
17.26
GG
15.95
16.20
Note. IL6 = interleukin 6; SNP = single nucleotide polymorphism

Finally, for SNP rs16944 in gene IL1B, neither AA, AG, or GG genotypes were
associated with a difference in mean scores on fatigue severity, fatigue interference, pain
severity, or pain interference (see Table 6). There was no linear pattern from AA to AG to GG
for fatigue severity, with mean scores of 14.36, 13.81, and 15.66 respectively. Although there did
appear to be a linear pattern among scores for AA, AG, and GG for fatigue interference, with
mean scores of 24.14, 24.42, and 28.99 respectively, this was not significant (p = .417). There
was no linear pattern for pain severity genotypes, with AA, AG, and GG scores of 10.01, 7.60,
and 9.90 respectively. Finally, was no linear pattern for pain interference, with mean scores for
AA, AG, and GG genotypes of 15.93, 11.97, and 17.15 respectively.

54

Table 6. One-Way ANOVA Trend Analysis Between SNP rs16944 in gene IL1B and Pain and
Fatigue Scores
Symptom Outcome
Measure
Fatigue Severity

Genotype

Mean

SD

F

p-value

AA
AG
GG

14.36
13.81
15.66

7.59
8.12
7.98

.310

.578

AA
AG
GG

24.14
24.42
28.99

20.41
20.04
20.68

.662

.417

AA
AG
GG

10.07
7.60
9.90

7.18
7.91
8.55

.005

.943

AA
15.93
15.57
.065
AG
11.97
15.74
GG
17.15
17.29
Note. IL1B = interleukin 1 beta; SNP = single nucleotide polymorphism

.799

Fatigue Interference

Pain Severity

Pain Interference

In summary, the results of the aim 1 one-way linear ANOVAs that explored the
relationships between specific genotypes and fatigue or pain scores found no statistically
significant correlations (p’s > .05) for all SNPs.
Results Aim 2
The second aim of this study was to explore whether single nucleotide polymorphism
(SNP) rs1800795 in gene IL6, SNP rs16944 in gene IL1B, and SNP rs4680 in gene COMT,
moderate the effects of the MBSR(BC) intervention on fatigue and/or pain symptoms. Although
there were no linear relationships between genotypes and mean scores on FSI and BPI
measurements from Aim 1, the possibility of genetic moderation of FSI and BPI scores from
MBSR(BC) remained, as Aim 1 and Aim 2 were not conditional upon one another. Groups were
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compared by assignment (MBSR(BC) versus UC) and genotype (AA, AG, GG or CC, CG, GG)
to show the changes for mean fatigue and pain scores over 12 weeks between groups. This
allowed the exploration of potential genetic moderators of fatigue and/or pain symptoms in BCS
as well as moderation of fatigue and/or pain symptom outcomes resulting from the MBSR(BC)
intervention. Three models were used (Additive, Dominant, and Recessive for the polymorphic
alleles) and the model that fit the hypotheses best was included. To further explore genetic
moderation of fatigue and pain outcomes resulting from MBSR(BC), Linear Mixed Model
(LMM) analyses were performed. Again, three models (Additive, Dominant, and Recessive)
were used and the model that fit the hypotheses best was included.
COMT. For COMT SNP rs4680, when comparing mean scores between groups by
assignment (MBSR(BC) versus UC) and genotype (AA, AG, GG) during the active time of the
intervention (baseline to six weeks) through 12-week follow-up, it appeared that genotype may
have had an impact on fatigue severity scores (see Figure 3). In Figure 3, MBSR(BC)
participants with GG genotype scored higher for fatigue severity than other participants within
other groups at baseline. MBSR(BC) may have had a positive effect on fatigue severity for those
with GG genotype, as fatigue severity scores were higher at baseline and decreased more than
those with other genotypes (AA or AG) from baseline and 12 weeks. However, in this study, the
sample size was small and because the minor allele for SNP rs4680 was (G) and there were only
13 participants in the MBSR(BC) group with GG genotype (see table 3), this may have affected
the results as the higher baseline mean score among that group may have influenced the
regression to the mean.
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Figure 3. Fatigue Severity Scores from Baseline to 6 and 12 Weeks for COMT. A comparison of
means was used to compare improvement in fatigue severity scores between groups and explore
potential genetic moderation of outcomes. MBSR = mindfulness-based stress reduction for breast
cancer survivor group; UC = usual care group; UC AA = usual care group with AA genotype;
UC AG = usual care group with AG genotype; UC GG = usual care group with GG genotype;
MBSR AA = MBSR group with AA genotype; MBSR AG = MBSR group with AG genotype;
MBSR GG = MBSR group with GG genotype
To further explore the possibility that genotype moderated fatigue severity symptoms and
the effects of MBSR(BC), linear mixed models (LMM) were used to assess interactions between
time (baseline to 6 and 12 weeks), assignment (MBSR(BC) versus UC), and genotype (AA, AG,
or GG), which resulted in no significant findings.
Table 7 illustrates that the results of LMM show that fatigue severity scores seemed to
improve over time, regardless of assignment to MBSR(BC) or UC, which approached
significance F (2, 156) = 2.458, p = .089. However, there were no significant interactions
between time and genotype, time and assignment, or genotype and assignment at p’s > .05.
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Table 7. Linear Mixed Model Results for Fatigue Severity by Genotype, Assignment, and Time
for COMT rs4680
Source
df (num, den)
F value
p value
Time
Assignment
COMT Additive
Time*COMT Additive
Time*Assignment
COMT Additive*Assignment

(2, 156)
(1, 156)
(1, 156)
(4, 156)
(2, 156)
(2, 154)

2.458
.557
.391
1.070
1.383
1.667

.089
.457
.677
.374
.254
.192

Note. COMT = Catechol-O-methyltransferase gene; df = degrees of freedom; num = numerator;
den = denominator
There were also no significant findings for genetic moderation of fatigue interference for
COMT SNP rs4680. Figure 4 illustrates that genotype did not have an effect on scores in the
MBSR(BC) group, as participants with either AA, AG, or GG genotype all similarly benefited
from the intervention. However, among those with GG genotype, those in the MBSR(BC) group
had a decrease in fatigue interference scores from baseline to six weeks, whereas scores
increased in the UC group. To further explore the possibility that genotype moderated fatigue
interference and/or the effects of MBSR(BC), LMM were used and found no significant
interactions of time, assignment, or genotype.
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Figure 4. Fatigue Interference Scores from Baseline to 6 and 12 Weeks for COMT. A
comparison of means was used to compare improvement in fatigue interference scores between
groups and explore potential genetic moderation of outcomes. MBSR = mindfulness-based stress
reduction for breast cancer survivor group; UC = usual care group; UC AA = usual care group
with AA genotype; UC AG = usual care group with AG genotype; UC GG = usual care group
with GG genotype; MBSR AA = MBSR group with AA genotype; MBSR AG = MBSR group
with AG genotype; MBSR GG = MBSR group with GG genotype
Table 8 illustrates that neither time, MBSR(BC), or genotype affected fatigue
interference scores. This means that whether time passed, if participants were in the UC or
MBSR(BC) group, or if they had a specific genotype, these interactions did not contribute to a
decrease in fatigue interference.
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Table 8. Linear Mixed Model Results for Fatigue Interference by Genotype, Assignment, and
Time for COMT rs4680
Source
df (num, den)
F value
p value
Time
(2, 156)
2.088
.127
Assignment
(1, 156)
.528
.469
COMT Additive
(2, 156)
.297
.744
Time*COMT Additive
(4, 156)
1.018
.400
Time*Assignment
(2, 156)
1.211
.301
COMT Additive*Assignment
(2, 154)
.371
.690
Note. COMT = Catechol-O-methyltransferase gene; df = degrees of freedom; num = numerator;
den = denominator
A similar result occurred for pain severity scores for COMT SNP rs4680, with no
significant findings, Although Figure 5 illustrates that participants with GG genotype may have
benefited more from the MBSR(BC) intervention between baseline and six weeks than those
with AA or AG genotype, LMM were implemented and found no significant interaction.
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Figure 5. Pain Severity Scores from Baseline to 6 and 12 Weeks for COMT. A comparison of
means was used to compare improvement in pain severity scores between groups and explore
potential genetic moderation of outcomes. MBSR = mindfulness-based stress reduction for breast
cancer survivor group; UC = usual care group; UC AA = usual care group with AA genotype;
UC AG = usual care group with AG genotype; UC GG = usual care group with GG genotype;
MBSR AA = MBSR group with AA genotype; MBSR AG = MBSR group with AG genotype;
MBSR GG = MBSR group with GG genotype
Table 9 illustrates the results of LMM, which show that pain severity scores may have
improved over time, regardless of assignment to MBSR(BC) or UC, as the main effect of time
approached significance F (2, 156) = 2.548, p = .081. However, there were no significant
interactions for the main effects of assignment or genotype, nor interactions between time and
genotype, time and assignment, or genotype and assignment.
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Table 9. Linear Mixed Model Results for Pain Severity by Genotype, Assignment, and Time for
COMT rs4680
Source
df (num, den)
F value
p value
Time
(2, 156)
2.548
.081
Assignment
(1, 156)
.364
.547
COMT Additive
(2, 156)
.087
.917
Time*COMT Additive
(4, 156)
.710
.586
Time*Assignment
(2, 156)
.196
.822
COMT Additive*Assignment
(2, 154)
1.939
.147
Note. COMT = Catechol-O-methyltransferase gene; df = degrees of freedom; num = numerator;
den = denominator
When comparing mean scores from baseline to six and 12 weeks for pain interference for
COMT SNP rs4680, it did not appear that genotype had an effect on scores or moderated the
effects of MBSR(BC), as shown in Figure 6. MBSR(BC) participants with either AA, AG, or
GG genotype similarly benefited during the intervention (baseline to six weeks).
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Figure 6. Pain Interference Scores from Baseline to 6 and 12 Weeks for COMT. A comparison of
means was used to compare improvement in pain severity scores between groups and explore
potential genetic moderation of outcomes. MBSR = mindfulness-based stress reduction for breast
cancer survivor group; UC = usual care group; UC AA = usual care group with AA genotype;
UC AG = usual care group with AG genotype; UC GG = usual care group with GG genotype;
MBSR AA = MBSR group with AA genotype; MBSR AG = MBSR group with AG genotype;
MBSR GG = MBSR group with GG genotype
Table 10 illustrates the results of LMM, which further explored the possibility that
genotype moderated pain interference and the effects of MBSR(BC). Results suggest no
significant interactions for the main effects of time, assignment, or genotype, or the interactions
between time and genotype, time and assignment, and genotype by assignment.
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Table 10. Linear Mixed Model Results for Pain Interference by Genotype, Assignment, and Time
for COMT rs4680 (Additive Model)
Source
df (num, den)
F value
p value
Time
(2, 156)
2.122
.123
Assignment
(1, 156)
.153
.696
COMT Additive
(2, 156)
.266
.767
Time*COMT Additive
(4, 156)
.935
.445
Time*Assignment
(2, 156)
.460
.632
COMT Additive*Assignment
(2, 154)
.526
.592
Note. COMT = Catechol-O-methyltransferase gene; df = degrees of freedom; num = numerator;
den = denominator
IL1B. For IL1B SNP rs16944, when comparing mean scores from baseline to six and 12
weeks for fatigue severity, it did not appear that genotype had an effect on scores or moderated
the effects of MBSR(BC) (see Figure 7). MBSR(BC) participants with either AA, AG, or GG
genotype similarly benefited from the intervention between baseline and six weeks.
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Figure 7. Fatigue Severity Scores from Baseline to 6 and 12 Weeks for IL1B. A comparison of
means was used to compare improvement in fatigue severity scores between groups and explore
potential genetic moderation of outcomes. MBSR = mindfulness-based stress reduction for breast
cancer survivor group; UC = usual care group; UC AA = usual care group with AA genotype;
UC AG = usual care group with AG genotype; UC GG = usual care group with GG genotype;
MBSR AA = MBSR group with AA genotype; MBSR AG = MBSR group with AG genotype;
MBSR GG = MBSR group with GG genotype
Table 11 illustrates the results of LMM, which further explored the possibility that
genotype moderated fatigue severity and/or the effects of MBSR(BC). Results show that fatigue
severity scores may have improved over time, regardless of assignment to MBSR(BC) or UC, as
the main effect of time approached significance F (2, 156) = 2.670, p = .072. However, there
were no significant interactions for the main effects of assignment or genotype, nor interactions
between time and genotype, time and assignment, or genotype and assignment.
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Table 11. Linear Mixed Model Results for Fatigue Severity by Genotype, Assignment, and Time
for IL1B rs16944
Source
df (num, den)
F value
p value
Time
(2, 156)
2.670
.072
Assignment
(1, 156)
.642
.424
IL1B Additive
(2, 156)
.035
.966
Time*IL1B Additive
(4, 156)
.691
.599
Time*Assignment
(2, 156)
1.287
.279
IL1B Additive*Assignment
(2, 154)
.369
.692
Note. IL1B = Interleukin 1 beta gene; df = degrees of freedom; num = numerator; den =
denominator
When comparing mean scores from baseline to six and 12 weeks for fatigue interference
for IL1B SNP rs16944, it did appear that genotype may have moderated the effects of
MBSR(BC) (see Figure 8). Among those with AA genotype, those in the MBSR(BC) group had
a decrease in fatigue interference scores from baseline to six and 12 weeks, whereas scores
increased in the UC group. However, in this study, the sample size was small and because the
minor allele for SNP rs16944 was (A), this may have affected the results.
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Figure 8. Fatigue Interference Scores from Baseline to 6 and 12 Weeks for IL1B. A comparison
of means was used to compare improvement in fatigue interference scores between groups and
explore potential genetic moderation of outcomes. MBSR = Mindfulness-based stress reduction
for breast cancer survivor group; UC = Usual care group; UC AA = usual care group with AA
genotype; UC AG = usual care group with AG genotype; UC GG = usual care group with GG
genotype; MBSR AA = MBSR group with AA genotype; MBSR AG = MBSR group with AG
genotype; MBSR GG = MBSR group with GG genotype
To further explore the possibility that genotype moderated the effects of MBSR(BC) on
fatigue interference, LMM were implemented. Table 12 illustrates a decrease in fatigue
interference scores over time among both MBSR(BC) and UC groups, which approached
significance F (2, 156) =2.531, p = .083. This means that fatigue interference may have
improved over time, regardless of assignment or genotype. However, there were no significant
interactions for the main effect of assignment or genotype, nor for the interactions between time
and assignment, time and genotype, or genotype and assignment.
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Table 12. Linear Mixed Model Results for Fatigue Interference by Genotype, Assignment, and
Time for IL1B rs16944
Source
df (num, den)
F value
p value
Time
(2, 156)
2.531
.083
Assignment
(1, 163)
.604
.438
IL1B Additive
(2, 156)
.041
.960
Time*IL1B Additive
(4, 156)
.653
.625
Time*Assignment
(2, 156)
1.104
.334
IL1B Additive*Assignment
(2, 154)
.484
.617
Note. IL1B = Interleukin 1 beta gene; df = degrees of freedom; num = numerator; den =
denominator
When comparing mean scores from baseline to six and 12 weeks for IL1B SNP rs16944,
it appeared that genotype possibly moderated pain severity in the MBSR(BC) group, as those
with AG genotype seemed to benefit less from the intervention (baseline to six weeks) than those
with AA or AG genotype (see Figure 9).
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Figure 9. Pain Severity Scores from Baseline to 6 and 12 Weeks for IL1B. A comparison of
means was used to compare improvement in pain severity scores between groups and explore
potential genetic moderation of outcomes. MBSR = Mindfulness-based stress reduction for
breast cancer survivor group; UC = Usual care group; UC AA = usual care group with AA
genotype; UC AG = usual care group with AG genotype; UC GG = usual care group with GG
genotype; MBSR AA = MBSR group with AA genotype; MBSR AG = MBSR group with AG
genotype; MBSR GG = MBSR group with GG genotype
To further explore the possibility that genotype moderated pain severity and/or the effects
of MBSR(BC), LMM were implemented. Table 13 illustrates that LMM resulted in no
significant findings for the main effects of time, assignment, or genotype, nor for interactions
between time and genotype, time and assignment, or genotype and assignment.
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Table 13. Linear Mixed Model Results for Pain Severity by Genotype, Assignment, and Time for
IL1B rs16944
Source
df (num, den)
F value
p value
Time
(2, 156)
.638
.530
Assignment
(1, 158)
.730
.394
IL1B Additive
(2, 156)
.623
.538
Time*IL1B Additive
(4, 156)
.301
.877
Time*Assignment
(2, 156)
.381
.684
IL1B Additive*Assignment
(2, 154)
.110
.896
Note. IL1B = Interleukin 1 beta gene; df = degrees of freedom; num = numerator; den =
denominator
When comparing mean scores from baseline to six and 12 weeks for IL1B SNP rs16944,
it did not appear that genotype moderated pain interference or the effects of MBSR(BC) (see
Figure 10). However, Figure 10 illustrates the lasting effects of MBSR(BC), as intervention
participants experienced a decrease in pain interference even after the end of six weeks, which
continued until 12-week follow up.
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Figure 10. Pain Interference Scores from Baseline to 6 and 12 Weeks for IL1B. A comparison of
means was used to compare improvement in pain interference scores between groups and
explore potential genetic moderation of outcomes. MBSR = Mindfulness-based stress reduction
for breast cancer survivor group; UC = Usual care group; UC AA = usual care group with AA
genotype; UC AG = usual care group with AG genotype; UC GG = usual care group with GG
genotype; MBSR AA = MBSR group with AA genotype; MBSR AG = MBSR group with AG
genotype; MBSR GG = MBSR group with GG genotype
Lastly, to further explore the possibility that genotype moderated pain interference and/or
the effects of MBSR(BC), LMM were used but found no significant results. However, table 14
illustrates a decrease in pain interference scores over time among both MBSR(BC) and UC
groups, which approached significance F (2, 156) =2.959, p = .055. This means that pain
interference may have improved over time, regardless of assignment or genotype. However,
there were no significant results for the main effects of assignment or genotype, nor for the
interactions between time and genotype, time and assignment, or genotype and assignment.
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Table 14. Linear Mixed Model Results for Pain Interference by Genotype, Assignment, and Time
for IL1B rs16944
Source
df (num, den)
F value
p value
Time
(2, 156)
2.959
.055
Assignment
(1, 161)
.279
.598
IL1B Additive
(2, 156)
.137
.872
Time*IL1B Additive
(4, 156)
1.658
.163
Time*Assignment
(2, 156)
.449
.639
IL1B Additive*Assignment
(2, 154)
.143
.867
Note. IL1B = Interleukin 1 beta gene; df = degrees of freedom; num = numerator; den =
denominator
IL6. For IL6 SNP rs1800795, when comparing mean scores from baseline to six and 12
weeks for fatigue severity for IL6 SNP rs1800795, it did appear that genotype and assignment
had a moderating effect on fatigue severity (see Figure 11). Among those with CG genotype,
participants in the MBSR(BC) group experienced a decrease in fatigue severity scores during the
active time of the intervention (baseline to six weeks).
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Figure 11. Fatigue Severity Scores from Baseline to 6 and 12 Weeks for IL6. A comparison of
means was used to compare improvement in fatigue severity scores between groups and explore
potential genetic moderation of outcomes. MBSR = Mindfulness-based stress reduction for
breast cancer survivor group; UC = Usual care group; UC CC = usual care group with CC
genotype; UC CG = usual care group with CG genotype; UC GG = usual care group with GG
genotype; MBSR CC = MBSR group with CC genotype; MBSR CG = MBSR group with CG
genotype; MBSR GG = MBSR group with GG genotype
To further explore the possibility that assignment and genotype moderated the outcome
of fatigue severity, LMM were used and found a significant interaction F (2, 154) = 5.172, p =
.007 (see table 15). This suggests that being in the MBSR(BC) group and having a specific
genotype affected fatigue severity scores.
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Table 15. Linear Mixed Model Results for Fatigue Severity by Genotype, Assignment, and Time
for IL6 rs1800795
Source
df (num, den)
F value
p value
Time
(2, 156)
1.305
.274
Assignment
(1, 156)
.714
.399
IL6 Additive
(2, 156)
1.944
.147
Time*IL6 Additive
(4, 156)
1.065
.376
Time*Assignment
(2, 156)
1.727
.181
IL6 Additive*Assignment
(2, 154)
5.172
.007*
Note. IL6 = Interleukin 6 gene; df = degrees of freedom; num = numerator; den = denominator;
*p<.05
Table 16 reports mean scores and standard deviations for fatigue severity at baseline and
12 weeks for IL6 by assignment and genotype, which further supports the results displayed in
Figure 11. It may be interpreted that MBSR participants with CG genotype experienced the
largest drop in fatigue severity scores from 17.08 at baseline to 10.97 at 12 weeks, with a
medium to large effect size of d = 0.72.
Table 16. Mean Scores and Standard Deviations for Fatigue Severity at Baseline and 12 Weeks
for IL6 rs1800795 by Assignment and Genotype
Group
Baseline
12 Weeks
Assignment and Genotype
Mean
Standard
Mean
Standard
Deviation
Deviation
UC CC
13.40
8.396
10.27
7.754
UC CG
11.71
7.191
11.42
8.397
UC GG
16.94
8.207
15.35
9.120
MBSR CC
15.21
7.591
12.91
8.093
MBSR CG
17.08
8.977
10.97
7.829
MBSR GG
13.68
6.412
12.18
6.532
There was a similar finding when comparing mean scores from baseline to six and 12
weeks for fatigue interference for IL6 SNP rs1800795. Figure 12 illustrates that it did appear that
genotype had a moderating effect on the decrease in scores resulting from MBSR(BC). Overall,
participants in the MBSR(BC) group seemed to experience a greater decrease in mean scores for
fatigue interference if they had CG genotype versus CC or GG genotypes.
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Figure 12. Fatigue Interference Scores from Baseline to 6 and 12 Weeks for IL6. A comparison
of means was used to compare improvement in fatigue interference scores between groups and
explore potential genetic moderation of outcomes. MBSR = Mindfulness-based stress reduction
for breast cancer survivor group; UC = Usual care groupUC CC = usual care group with CC
genotype; UC CG = usual care group with CG genotype; UC GG = usual care group with GG
genotype; MBSR CC = MBSR group with CC genotype; MBSR CG = MBSR group with CG
genotype; MBSR GG = MBSR group with GG genotype
To further explore this possibility, LMM were implemented and found a significant
interaction F (2, 154) = 3.548, p = .031 between genotype and assignment (see table 16). This
suggests that being in the MBSR(BC) group and having a specific genotype affected fatigue
interference scores.
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Table 17. Linear Mixed Model Results for Fatigue Interference by Genotype, Assignment, and
Time for IL6 rs1800795
Source
df (num, den)
F value
p value
Time
(2, 156)
1.066
.347
Assignment
(1, 158)
.600
.440
IL6 Additive
(2, 155)
1.817
.166
Time*IL6 Additive
(4, 156)
1.143
.339
Time*Assignment
(2, 156)
1.538
.218
IL6 Additive*Assignment
(2, 154)
3.548
.031*
Note. IL6 = Interleukin 6 gene; df = degrees of freedom; num = numerator; den = denominator;
*p<.05
Table 18 reports mean scores and standard deviations for fatigue interference at baseline
and 12 weeks for IL6 by assignment and genotype, which further supports the results displayed
in Figure 12. It may be interpreted that MBSR participants with CG genotype experienced the
largest drop in fatigue interference scores from 30.31 at baseline to 20.29 at 12 weeks, with a
small to medium effect size of d = 0.48.
Table 18. Mean Scores and Standard Deviations for Fatigue Interference at Baseline and 12
Weeks for IL6 rs1800795 by Assignment and Genotype
Group
Baseline
12 Weeks
Assignment and Genotype
Mean
Standard
Mean
Standard
Deviation
Deviation
UC CC
25.10
20.212
17.20
14.242
UC CG
18.80
16.629
18.45
18.970
UC GG
33.34
21.977
28.74
21.288
MBSR CC
24.27
18.932
24.09
23.704
MBSR CG
30.31
22.280
20.29
19.170
MBSR GG
26.14
19.125
18.18
12.681
When comparing mean scores from baseline to six and 12 weeks for pain severity for IL6
SNP rs1800795, it did appear that genotype had a moderating effect on the decrease in scores
resulting from MBSR(BC) (see Figure 13). Participants with CG genotype appeared to benefit
more from MBSR(BC) from baseline to six weeks than those with CC or GG genotypes. From
baseline to six weeks, pain severity scores actually increased in MBSR(BC) participants with CC
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genotype, and at 12 weeks, pain severity scores returned to baseline levels, showing no benefit of
MBSR(BC). Similarly, MBSR(BC) participants with GG genotype experienced an increase in
pain severity scores from baseline to six weeks, showing no benefit during the intervention
period.

Figure 13. Pain Severity Scores from Baseline to 6 and 12 Weeks for IL6. A comparison of
means was used to compare improvement in pain severity scores between groups and explore
potential genetic moderation of outcomes. MBSR = Mindfulness-based stress reduction for
breast cancer survivor group; UC = Usual care groupUC CC = usual care group with CC
genotype; UC CG = usual care group with CG genotype; UC GG = usual care group with GG
genotype; MBSR CC = MBSR group with CC genotype; MBSR CG = MBSR group with CG
genotype; MBSR GG = MBSR group with GG genotype
To further explore the possibility that genotype moderated the outcome of pain severity
within the MBSR(BC) group, LMM were used and confirmed a significant interaction between
genotype and assignment F (2, 154) = 4.294, p = .015 (see table 17).
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Table 19. Linear Mixed Model Results for Pain Severity by Genotype, Assignment, and Time for
IL6 rs1800795 (Additive Model)
Source
df (num, den)
F value
p value
Time
(2, 156)
.974
.380
Assignment
(1, 156)
.430
.513
IL6 Additive
(2, 155)
.722
.488
Time*IL6 Additive
(4, 156)
.658
.622
Time*Assignment
(2, 156)
.250
.779
IL6 Additive*Assignment
(2, 154)
4.294
.015*
Note. IL6 = Interleukin 6 gene; df = degrees of freedom; num = numerator; den = denominator;
*p<.05
Table 20 reports mean scores and standard deviations for pain severity at baseline and 12
weeks for IL6 by assignment and genotype, which further supports the results displayed in
Figure 13. It may be interpreted that MBSR participants with CG genotype experienced the
largest drop in pain severity scores from 10.86 at baseline to 7.38 at 12 weeks, with a small to
medium effect size of d = 0.41.
Table 20. Mean Scores and Standard Deviations for Pain Severity at Baseline and 12 Weeks for
IL6 rs1800795 by Assignment and Genotype
Group
Baseline
12 Weeks
Assignment and Genotype
Mean
Standard
Mean
Standard
Deviation
Deviation
UC CC
9.60
9.97
5.70
7.24
UC CG
7.02
7.65
5.93
6.37
UC GG
10.72
7.50
10.02
7.79
MBSR CC
8.09
6.55
7.91
9.04
MBSR CG
10.86
9.57
7.38
7.39
MBSR GG
6.86
7.17
4.71
7.29
Finally, for pain interference, a comparison of mean scores from baseline to six and 12
weeks for IL6 SNP rs1800795 suggested that genotype had a moderating effect on pain
interference scores resulting from MBSR(BC) (see Figure 14).
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Figure 14. Pain Interference Scores from Baseline to 6 and 12 Weeks for IL6. A comparison of
means was used to compare improvement in pain interference scores between groups and
explore potential genetic moderation of outcomes. MBSR = Mindfulness-based stress reduction
for breast cancer survivor group; UC = Usual care group; UC CC = usual care group with CC
genotype; UC CG = usual care group with CG genotype; UC GG = usual care group with GG
genotype; MBSR CC = MBSR group with CC genotype; MBSR CG = MBSR group with CG
genotype; MBSR GG = MBSR group with GG genotype
To further explore the possibility that genotype moderated the outcome of pain
interference within the MBSR(BC) group, LMM were implemented and confirmed a significant
interaction between genotype and assignment F (2, 154) = 3.577, p = .030 (see table 18). This
means that among MBSR(BC) participants, having a specific genotype affected pain interference
scores.
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Table 21. Linear Mixed Model Results for Pain Interference by Genotype, Assignment, and Time
for IL6 rs1800795
Source
df (num, den)
F value
p value
Time
(2, 156)
1.147
.320
Assignment
(1, 157)
.221
.639
IL6 Additive
(2, 155)
1.508
.224
Time*IL6 Additive
(4, 156)
.761
.552
Time*Assignment
(2, 156)
.660
.518
IL6 Additive*Assignment
(2, 154)
3.577
.030*
Note. IL6 = Interleukin 6 gene; df = degrees of freedom; num = numerator; den = denominator;
*p<.05
Table 22 reports mean scores and standard deviations for pain interference at baseline
and 12 weeks for IL6 by assignment and genotype, which further supports the results displayed
in Figure 14. It may be interpreted that MBSR participants with CG genotype experienced the
largest drop in pain interference scores from 18.19 at baseline to 11.95 at 12 weeks, with a small
to medium effect size of d = 0.38.
Table 22. Mean Scores and Standard Deviations for Pain Interference at Baseline and 12 Weeks
for IL6 rs1800795 by Assignment and Genotype
Group
Baseline
12 Weeks
Assignment and Genotype
Mean
Standard
Mean
Standard
Deviation
Deviation
UC CC
14.20
18.16
16.00
24.55
UC CG
10.41
14.72
8.08
11.61
UC GG
19.66
16.95
21.84
26.46
MBSR CC
12.18
12.77
7.95
12.40
MBSR CG
18.19
19.13
11.95
13.81
MBSR GG
19.66
16.95
21.84
26.46
In summary, there were no significant findings for SNP rs4680 in COMT or SNP rs16944
in IL1B. However, the results from LMM analyses suggest that time may have been in a factor in
the improvement of fatigue severity and pain severity when assessing COMT and for fatigue
severity, fatigue interference, and pain severity when assessing IL1B. Several significant findings
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resulted from LMM when assessing IL6. First, LMM resulted in a significant interaction between
genotype and assignment. Second, a comparison of means suggests that participants in the
MBSR(BC) group who had CG genotype benefited more from the intervention than those with
CC or GG genotypes for fatigue severity, fatigue interference, pain severity, and pain
interference, with small to large effect sizes ranging from d = 0.38 to d = 0.72.
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Chapter Five
Summary, Discussion, Conclusions, Implications, and Recommendations for Future Study
Introduction
The final chapter of the dissertation includes a summary of the study and a discussion of
the results, conclusions including limitations, implications for nursing, and future research
recommendations. The purpose of this study was to identify specific genotypes involved in
fatigue and pain symptoms and explore whether SNP rs16944 in gene IL1B, SNP rs4680 in gene
COMT, and SNP rs1800795 in gene IL6 moderate fatigue and/or pain outcomes in BCS and
whether the effects of the MBSR(BC) intervention on fatigue and/or pain are moderated by these
SNPs. This genetic study and secondary data analysis conducted within the R01 MBSR Symptom
Cluster Trial for Breast Cancer Survivors, 1R01CA131080.
Discussion and Conclusions
This study yielded several important findings. First, in this study of 158 BCS, most
participants were married, college-educated (75.3%), with an average age of 58.4 years, and had
an average annual household income of $40,000-$80,000, which were similar to the
demographic characteristics within the parent R01 study (N = 322). The subsample of this study
(N = 158) were not racially diverse as the sample size was too small to compare genetic
associations across different racial groups and was therefore limited to non-Hispanic and
Hispanic whites. In terms of clinical characteristics, most BCS were diagnosed with Stage I-II
BC (72.8%), received mastectomy (58.9%), and received a combination of chemotherapy and
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radiation (30.4%), and received hormone treatment (64.6%), which were similar to clinical
characteristics in the parent study. Among the 158 participants in this study, there were no
significant differences in age, stage of cancer, or type of cancer treatment, between MBSR(BC)
(n = 75) and UC (n = 83) groups in this study. However, there were significantly more (p = .04)
participants in the UC group (83.1%) within one year from end of cancer treatment compared to
the MBSR(BC) group (69.3%), which may help explain why UC participants also experienced
an improvement in fatigue and pain symptoms during the study, as they were closer to treatment
end and may have been focused on trying to overcome adverse symptoms to continue with daily
activities.
A second finding of this study was that there were no significant correlations between
SNPs COMT rs4680, IL1B rs16944, and IL6 rs1800975, and fatigue and pain symptoms at
baseline. The results from one-way linear ANOVAs, which were implemented to identify
specific genotypes associated with fatigue and pain symptoms from Aim 1, found no linear
relationships between genotypes and mean scores on FSI and BPI measurements. Previous
research has found associations between pain and SNPs in COMT rs4680, IL1B rs16944, and IL6
rs1800795. For SNP COMT rs4680, the results from previous research have been mixed for
associations between +/- pain severity and (A) and (G) alleles, with two studies (Knisely et al.,
2018; Tammimaki & Mannisto, 2012) reporting positive associations between (A) alleles and
increased pain, and another study (Rut et al., 2014) reporting a positive association between (G)
alleles and increased pain. The COMT enzyme is responsible for metabolizing catechol
neurotransmitters (dopamine, adrenaline, and noradrenaline) in the brain’s prefrontal cortex. The
(G) allele codes for valine amino acid, which results in more COMT enzyme available to
metabolize catechol neurotransmitters and thus less extracellular dopamine, which may result in
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a higher pain threshold and resilience to stress (Stein, Newman, Savitz, & Ramesar, 2006).
Considering the previous research results between genotypes for SNP COMT rs4680 and pain
have been mixed, and there were no significant associations found in this study, more research is
needed in this area to confirm the genetic effects on the pain symptom experience. Second, for
SNP IL1B rs16944, the results from previous research on the associations between genotype and
fatigue have also been mixed. A study by Kober et al., 2016 reported an association between CG
or GG genotype and higher levels of fatigue, a study by Jim et al., 2012 found no association,
and a study by Collado-Hidalgo et al., 2008 reported an association between CC genotype and
higher levels of fatigue. The IL1B gene provides instructions for producing pro-inflammatory
IL1B cytokine protein, an important mediator involved in the inflammatory response, increased
plasma levels of IL1B promote inflammation. It is unclear which genotypes promote increases in
plasma IL1B. Considering the previous research results between genotypes for SNP IL1B
rs16944 and fatigue have been mixed, and there were no significant associations found in this
study, more research is needed in this area to confirm the genetic effects on the fatigue symptom
experience. Finally, for SNP IL6 rs1800795, the results from previous research have been mixed
for associations between +/- fatigue severity and genotype, with one study (Collado-Hidalgo et
al., 2008) reporting an association between both GG or CC genotype and higher levels of fatigue
versus CG genotype, two studies (Bower et al., 2013; Shi et al., 2014) reporting an association
between GG genotype and higher levels of fatigue, and one study (Jim et al., 2012) reporting an
association between CG genotype and higher levels of fatigue. Similar to the actions of the IL1B
gene, the IL6 gene provides instructions for producing pro-inflammatory IL6 cytokine protein
that is an important mediator involved in the inflammatory response and increased plasma levels
of IL6 promote inflammation. It is unclear which genotypes promote increases in plasma IL6 and
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considering previous research findings have been mixed for associations between SNP IL6
rs16944 and +/- fatigue severity, more research is needed to confirm its effects on the fatigue
symptom experience.
A third finding of this study is that those in the MBSR(BC) group who had CG genotype
for IL6 benefited more from the intervention than those with CC or GG genotypes for fatigue
severity (p = .007, d = 0.72), fatigue interference (p = .031, d = 0.48), pain severity (p = .015, d =
0.41), and pain interference (p = .030, d = 0.38. Although there were no significant findings
identified from Aim 1, this did not mean that genotype could not moderate a change in symptom
scores resulting from an intervention such as MBSR(BC). Therefore, a mixed model approach
was then implemented to explore whether SNP rs1800795 in gene IL6, SNP rs16944 in
gene IL1B, and SNP rs4680 in gene COMT, moderated the effects of the MBSR(BC)
intervention on fatigue and/or pain symptoms from Aim 2. Linear mixed models analyzed
genotype, assignment, and time as main effects along with the interaction of genotype x time,
genotype x assignment (MBSR(BC) versus UC), and assignment x time. First, an interesting
finding from Aim 2 results was that regardless of assignment, participants experienced an
improvement in symptoms over time. This may mean that MBSR(BC) was an effective treatment
for participants within the intervention group during the active time of the intervention, and
control group participants may have become more attentive and concerned over their symptoms
and found other ways to improve their symptoms. In the parent study, MBSR(BC) was
demonstrated as an effective therapy for fatigue severity and interference (p’s < .01), with a
small effect size for fatigue severity (d = 0.27) (Lengacher et al., 2016). Additional research has
supported MBSR for the treatment of fatigue symptoms (Carlson & Garland, 2005) and although
the parent study did not find benefit from MBSR for pain symptoms, another study found
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promising results (Kvillemo & Branstrom, 2011). In this study, the significant interaction found
between genotype and assignment suggests that MBSR(BC) participants with CG genotype for
IL6 experience a greater improvement in fatigue severity, fatigue interference, pain severity, and
pain interference than those with CC or GG genotypes. Among other genetic studies, the results
have been mixed, with some studies (Collado-Hidalgo et al., 2008; Jim et al., 2012) suggesting
that CC or CG genotype predicts more fatigue and other studies (Bower et al., 2013; ColladoHidalgo et al., 2008) suggesting GG genotype predicts higher levels of fatigue. There are no
positive findings on the association between pain and SNP IL6 rs1800795 among BCS in the
literature. However, previous research suggests that increased plasma levels of pro-inflammatory
cytokine IL6 are associated with pain and SNP rs1800795 influences its expression rate (Kovacs
et al., 2016). Results from this study provide preliminary evidence that SNPs in genes associated
with inflammatory pathways moderate the effects of MBSR(BC) on improvements fatigue and
pain symptoms in BCS and supports the hypothesis that MBSR reduces symptoms by improving
the stress response (Kabat-Zinn, 1990; Kabat-Zinn et al., 1985, 1992). Fatigued BCS have been
found to have increased plasma levels of IL6, IL1B, and other markers of inflammation (Bower
et al., 2007; Collado-Hidalgo et al., 2006). Considering mind-body therapies have been found to
reduce plasma levels of inflammatory cytokines such as IL6 (Morgan et al., 2014), a speculation
may be made that stress-reducing programs such as MBSR(BC) help decrease inflammation in
the body by reducing inflammatory cytokine levels and thus improve fatigue and/or pain
symptoms.
Exploring these associations and disseminating findings will contribute to symptom
science and precision medicine by targeting optimal therapies for BCS based on their genetic
profiles, which may help improve quality of life. As the symptom experience varies by
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individual based on genetic and environmental backgrounds, medicine should not follow a “onesize-fits-all” approach. Mind-body therapies such as MBSR(BC) are finally entering the spotlight
in medicine research. Although this study is the first reported study to explore the genetic
moderation of fatigue and/or pain symptoms in BCS participating in a MBSR(BC) program, it
further supports previous research (Lengacher et al., 2015b) which found genetic moderation of
MBSR(BC) on cognitive impairment in BCS. The major benefit of this study is to support future
genetic research and precision medicine to help predict which treatments are more advantageous
for patients based on their individual genes. The major aim of the Precision Medicine Initiative
is to expand cancer genomics to develop better treatment methods and during President Barack
Obama’s State of the Union address, $215 million was invested towards biomedical advances to
help supply healthcare providers with new knowledge and tools to personalize treatments for the
best outcomes (The White House, 2015). By first discovering genetic changes and their
associations, further research can then test targeted interventions on patients to determine the
best outcomes. This genetic study is a step towards both identifying genetic associations with
adverse symptoms such as pain and fatigue experienced by BCS, and exploring the genetic
moderation of MBSR(BC) on such symptoms.
Limitations
There are several limitations of this study that should be mentioned. First, the sample size
was small for a genetic study. Sufficient statistical power is critical for the detection of genetic
association and moderation studies. Testing one SNP requires 248 cases, under the assumption of
an odds ratio of 2, 5% prevalence, 5% minor allele frequency, 1:1 case/control ratio, and a 5%
error rate (Hong & Park, 2012). This current study had enrolled 158 participants and tested three
SNPs: COMT rs4680, IL1B rs16944, and IL6 rs1800795. However, this study was exploratory in
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nature with a goal of identifying associations and moderation of effects that should be researched
in larger future studies. A second limitation was that this study explored the presence or absence
of SNPs and their association with symptoms experienced by BCS, however, it does not address
gene expression. The results of this study do not bridge the gap between the presence of SNPs
and their effects on protein synthesis. The study of gene expression can help explain the
variability of a SNP’s effect on symptoms and increase the power of detecting their overall
effects (Huang, VanderWeele, & Lin, 2014). Another limitation is that although specific
genotypes were explored among genes involved in inflammatory and anti-inflammatory
pathways, there were no direct measures of systemic levels of circulating IL6 and IL1B, which
would have provided additional information on the underlying mechanisms for pain and fatigue
severity. Current empirical research has primarily focused on circulating inflammatory markers,
which has generally shown a positive association with fatigue and pain, particularly after the end
of cancer treatment (Miaskowski & Aouizerat, 2012). In addition, since there was no assessment
of fatigue or pain prior to a breast cancer diagnosis, so it is impossible to determine if there were
pre-existing symptoms prior to cancer treatment. Since there was no healthy control group,
inferences cannot be made about the relationship between these genetic variations and fatigue
and pain in the general population or in people with other types of cancer (prostate, lung, etc.).
Furthermore, this study included only Hispanic and non-Hispanic white women; generalizations
to women of other races and men are limited. Finally, even though participants were randomized,
the MBSR(BC) and UC groups were significantly (p < .05) different in terms of time since the
end of their cancer treatment. The UC group was closer to cancer treatment end (< 1 year) than
the MBSR(BC) group, which may have diminished the potential to determine the true influence
of the MBSR(BC) intervention.
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Implications for Nursing
The nurse caring for BCS should be knowledgeable of the individual variations in fatigue
and pain experiences, which may be influenced by genetic background. As healthcare moves
forward into the era of precision medicine, the nurse should also be aware that because of these
genetic differences, some patients may respond more or less to treatments aimed at improving
adverse symptoms experienced by patients after cancer treatment. As the implementation of
precision medicine moves forward, nurses must continue providing care while optimizing patient
outcomes. The nurse should also be informed of non-pharmacological treatments such as
MBSR(BC), as discussions between the nurse and patient may occur regarding unpleasant
symptoms resulting from cancer treatment and/or the cancer experience, and the nurse should be
prepared to discuss what is available to the patient. Finally, educational programs should be
further implemented to provide nurses a basic understanding of precision medicine, to help them
understand how genetics influence subjective symptoms as well as treatment outcomes.
Recommendations for future research. This was the first study to explore whether
SNPs moderate the effects of a MBSR(BC) intervention on pain and/or fatigue. Although the
exact mechanisms for fatigue and pain resulting from cancer treatment are largely unknown,
genetic factors play a role (Doong et al., 2015; Shi et al., 2015) and genetic studies can
contribute to the field of precision medicine, to tailor complementary and alternative medicine
therapies to best suit patients’ needs (Grady & Gough, 2015). The future research
recommendations, based on the findings of this current study as well as the existing scientific
literature in this area of research, include the following:
1. To conduct additional research exploring associations between SNPs in genes and other
distressing symptoms experienced by BCS after treatment.
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2. To conduct a study exploring genetic moderation of symptom outcomes resulting from
MBSR(BC) with a larger sample size and include a healthy (non-cancer) control group.
3. To perform a study similar to this but including other racial backgrounds. This study was
conducted only on Hispanic and non-Hispanic whites and the findings may not apply
to BCS with more diverse racial backgrounds. Although nucleotide diversity
between humans is about 0.1 percent, this study was limited to whites only since
the sample size would lack precision for other races, which were very few in the
parent study.
4. Combine studies of SNP analysis, gene expression, and measurement of circulating
inflammatory and ant-inflammatory markers in a study involving BCS participating in a
MBSR(BC) program for pain and fatigue.
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Appendix C. Brief Pain Inventory (Continued)
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Appendix C. Brief Pain Inventory (Continued)
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Appendix D: Institutional Review Board Approval

8/21/2017
Cecile Lengacher , Ph.D.
USF College of Nursing
12901 Bruce B. Downs Blvd. MDC-22
Tampa, FL 33612
RE: Expedited Approval of Amendment
IRB#: Ame12_107408
Title: Mindfulness-Based Stress Reduction (MBSR) Symptom Cluster Trial for Breast Cancer
Survivors
Dear Dr. Lengacher :
On 8/20/2017, the Institutional Review Board (IRB) reviewed and APPROVED your
Amendment. The submitted request and all documents contained within have been approved,
including those outlined below, as described by the study team:
Other changes: Allowing a doctoral student access to a deidentified data set for secondary
analysis. The doctoral student is Carissa Alinat and she has received a grant from Sigma Theta
Tau International (STTI) to fund her secondary analysis for her grant entitled "Genetic
Moderation of Pain and Fatigue in Breast Cancer Survivors Utilizing Mindfulness-Based Stress
Reduction"
Justification: The secondary analysis on the deidentified data set will allow this doctoral student
candidate to analyze the data specific to the Single Nucleotide Polymorphisms (SNPs) identified
without using any PHI. The purpose of this SITI grant is for the candidate to apply their
knowledge and related research by utilizing the data available through this R01 project. The
purpose of her research will assess whether specific SNPs (rs1800795 of gene IL6 and rs16944
in gene ILB1b moderate fatigue, and whether SNP rs4680 of COMT moderates pain) are
associated with any improvement with these symptoms after a behavioral intervention, the
Mindfulness-Based Stress Reduction for Breast Cancer (MBSR(BC)) program, which are within
the scope of the parent R01. There will no new data or samples to be collected for this secondary
data analysis.
As the principal investigator of this study, it is your responsibility to conduct this study in
accordance with USF HRPP policies and procedures and as approved by the USF IRB. Any
changes to the approved research must be submitted to the IRB for review and approval via an
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